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Abstract 
Chronic pancreatitis is a major risk factor for pancreatic ductal adenocarcinoma (PDAC), one of 
the deadliest cancer types. During the progression to cancer the inflammatory-harmed tissue 
undergoes formations such as acinar to ductal metaplasia (ADM), pancreatic intraepithelial 
neoplasia (PanIN) and epithelial mesenchymal transition (EMT). Previously it has been shown 
that MMP3 and Rac1b play important roles during the progression of lung and mammary cancer 
and transition in different cell lines. To investigate whether MMP3 and Rac1b have an influence 
on the development and progression of pancreatic cancer, different cell lines for in vitro and 
two triple transgenic mouse models (rtTA-Ela1/tet-HA-MMP3/tet-KRAs and rtTA-Ela1/tet-YFP-
Rac1b/tet-KRas) for in vivo experiments were examined. The in vitro results were achieved by 
comparing different cell lines to the amount of endogenous MMP3 and Rac1b and the growth 
behavior. S2-007, an invasive and epithelial cell line, and MiaPaCa, a more mesenchymal 
behaving cell line, were the most promising ones and used for further investigations. To examine 
the effects on EMT, the cells were treated with recombinant protein or adenoviral constructs to 
overexpress MMP3 and Rac1b and screened for EMT marker proteins by RT-qPCR. The results 
show an influence of MMP3 and Rac1b on EMT machinery mainly in S2-007 cells and less in 
MiaPaCa cells. In the same way, a higher migration potential in S2-007 cells after MMP3 
overexpression was found by using a wound healing assay performed. The infection with 
adenoviral constructs showed different effects on EMT marker expression compared to the 
ectopic expression with recombinant proteins. Additionally, both kinds of treatment resulted in 
higher Rac1b, E-cadherin, and Vimentin expression levels on Plastic than on Matrigel. 
For in vivo experiments mice were treated for 5 months either with NaCl or Caerulein to induce 
chronic pancreatitis. The transgene was activated by using a reverse tetracycline-dependent 
promotor. The expectation that KRas on the background of chronic pancreatitis drives forward 
the tissue alterations to pancreatic cancer could not be confirmed, but ADM was found, what is 
one of the pre-stages of PDAC. 
All these findings suggested that MMP3 and Rac1b seem not to influence the EMT machinery in 
pancreatic tissue as much as expected, especially under in vivo conditions. Here additional 
pathways, such as TGFβ or NFκB signaling, seem to prefer Rac1b as interaction partner to 
promote EMT. 
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Zusammenfassung 
Die chronische Pankreatitis ist der Hauptrisikofaktor für die Entstehung eines duktalen 
Adenokarzinoms des Pankreas (PDAC). Während der Entwicklung zum Karzinom, durchläuft das 
belastete Gewebe verschiedene Vorläuferstadien, wie z.B. die azinäre-duktale Metaplasie 
(ADM), intraepitheliale Neoplasie des Pankreas (PanIN) und die epithelial-mesenchymale 
Transition (EMT). Es ist bekannt, dass MMP3 und Rac1b wichtige Rollen während der Entstehung 
von Brust- und Lungenkrebs und der EMT in Krebszelllinien im Allgemeinen spielen. Um 
herauszufinden, ob MMP3 und Rac1b auch einen Einfluss auf die Entstehung und Entwicklung 
von Pankreaskarzinomen haben, untersuchte ich verschiedene Zelllinien und nutzte zwei 
dreifach transgenen Mausmodelle (rtTA-Ela1/tet-HA-MMP3/tet-KRAs and rtTA-Ela1/tet-YFP-
Rac1b/tet-KRas). Für die in vitro Experimente wurden verschiedene Zelllinien auf ihren 
endogenen Gehalt von MMP3 und Rac1b und ihr Wachstumsverhalten untersucht. Dabei stellte 
sich heraus, dass S2-007, eine sehr invasive, epitheliale Zelllinie, und MiaPaCa, eine eher 
mesenchymale Zelllinie, die vielversprechendsten Zelllinien sind, um die Effekte von MMP3 und 
Rac1b Überexpression auf die EMT zu untersuchen. Die Überexpression wurde durch die 
Behandlung mit rekombinanten Proteinen oder adenoviralen Konstrukten erreicht. 
Anschließend wurde die Expression typischer EMT-Marker mittels RT-qPCR untersucht. Es stellte 
sich heraus, dass MMP3 und Rac1b hauptsächlich in S2-007 und weniger in MiaPaCa Zellen einen 
Einfluss auf die EMT-Maschinerie zu haben scheinen. Auch das Migrationspotenzial wurde 
maßgeblich in S2-007 Zellen durch die Überexpression von MMP3 erhöht. Die Infektion mit 
adenoviralen Konstrukten zeigte andere Effekte auf die EMT-Marker Expression als die 
Behandlung mit rekombinantem Protein. Außerdem zeigten sich auf Plastik für beide 
Behandlungsarten höhere Expressionslevel für Rac1b, E-cadherin und Vimentin als auf Matrigel. 
Während der in vivo Experimente wurden die Mäuse für 5 Monate mit Caerulein behandelt, um 
eine chronische Pankreatitis hervorzurufen. Die Transgenaktivierung erfolgte über einen 
reversen Tetracyclin abhängigen Promotor. Die Annahme, dass KRas auf einem Hintergrund der 
chronischen Pankreatitis, die entstehenden Gewebsveränderungen bis zum Karzinom 
vorantreibt, konnte nicht bestätigt werden. Jedoch konnte ich das Auftreten von ADM 
nachweisen, welche eine der Vorstufen des PDAC darstellt. 
Die erzielten Ergebnisse deuten darauf hin, dass MMP3 und Rac1b speziell unter in vivo 
Bedingungen einen geringeren Einfluss auf die EMT-Maschinerie haben, wie erwartet. Hier 
scheint es, dass EMT-Signalwege, die an Rac1b gebunden sind (z.B. TGFβ und NFκB), vor MMP3-
assoziierten Wegen, bevorzugt werden. 
Schlagworte: Chronische Pancreatitis, PDAC, ADM, PanIN, EMT, MMP3, Rac1b  
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 1 Introduction 
1. Introduction 
1.1. Pancreatic Cancer 
Cancer is a disease characterized by uncontrolled growth and spread of abnormal cells 
(American Cancer Society 2013). The prerequisite for a normal cell to become abnormal is the 
irreparable damage of its DNA. This can be caused by external factors such as tobacco, chemicals 
or radiation or by internal factors such as spontaneous mutations and stress signals (American 
Cancer Society 2013; Hanahan & Weinberg 2011). 
Normal cells possess strict control mechanisms for cell-cycle progression, undergoing apoptosis 
and many others. Cancer cells can evade some of these mechanisms to become immortal and 
to gain growth benefits. Douglas Hanahan and Robert Weinberg have suggested how a normal 
cell evolves to a neoplastic state or cancer cell in a series of events referred to as “Hallmarks of 
cancer”. These hallmarks are sustaining of proliferating signals, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating 
invasion and metastasis (Hanahan & Weinberg 2011). Different types of cancer show different 
strategies for survival, proliferation and dissemination during tumorigenesis. To acquire these 
functions additional hallmarks are necessary. One the one hand, the cells need the enabling 
characteristics “Tumor-promoting inflammation” and “Genomic instability and mutation”. On 
the other hand, the emerging hall marks “Deregulating cellular energetics” and “Avoiding 
immune destruction” are required to promote tumor progression (Hanahan & Weinberg 2011).  
The most common form of pancreatic cancer, and one of the deadliest types of cancer overall, 
is pancreatic ductal adenocarcinoma, short PDAC.  Late diagnosis in most cases leads to a high 
rate of advanced tumors and distant metastases at initial diagnosis. Only half of the patients at 
initial diagnosis represent good candidates for surgery, and in these, complete resection at 
surgery is achieved in only 60% of cases. Chemotherapy is conducive to prolong survival in a 
palliative setting, but cures less than 5% of patients (American Cancer Society 2016). The five-
year survival rate is about 7% in the US and Europe, meanwhile the death rates increase. This 
type of cancer is a disease of the elderly and the risk increases past the age of 50 (American 
Cancer Society 2013). Certain risk factors increase the risk to develop pancreatic cancer. Tobacco 
– smoked and unsmoked – is a major risk factor, whereas there is no clear evidence for alcohol 
(American Cancer Society 2013). In addition obesity, diabetes and a history of chronic 
pancreatitis can facilitate pancreatic cancer (Berrington de Gonzalez et al. 2003; Aune et al. 
2012; Stolzenberg-Solomon et al. 2005; Stocks et al. 2009; Raimondi et al. 2010; Guerra et al. 
2007). In some studies it has been shown that an infection with Hepatitis B or C virus as well as 
the infection with Helicobacter pylori may also increase the risk to develop pancreatic cancer 
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(Hassan et al. 2008; El-Serag et al. 2009; Risch et al. 2010). Among these risk factors the personal 
genetic background plays an important role for the development of pancreatic cancer. If there 
is a familiar history of pancreatic cancer, the risk is two-fold higher than in “normal” population. 
This risk increases for people with one first-degree relative with pancreatic cancer. If there are 
more than three first-degree relatives with pancreatic cancer, the risk rises up to 32-fold 
(Berrington de Gonzalez et al. 2003). Some of the genetic risk factors are mutated BRCA1 and 2 
genes, mutations in the CDKN2A gene (associated with FAMMM), and other cancer-related 
syndromes (Thompson & Easton 2002; Streff et al. 2016; Hahn et al. 2003; Couch et al. 2007; 
Slater et al. 2010; Bartsch et al. 2002; Lynch et al. 2002). Although there are no reliable methods 
for the early detection of pancreatic cancer in people with a familiar history of pancreatic cancer, 
there is an option of early detection and intervention in case of malignancy – the diagnosis of 
pancreatic intraepithelial neoplasia (PanINs) and the punctual resection of a part or the entire 
pancreas. PanINs represent a reorganisation of the pancreatic ductal epithelium with 
aggregation of histologic and genetic abnormalities (Maitra et al. 2003). In addition to 
intraductal papillary mucinous neoplasm, PanINs are the microscopic precursor lesions of PDAC 
(Singh & Maitra 2007). They are classified into different stages (Figure 1). The lowest grade is 
PanIN-1 with either a flat (1A) or papillary (1B) structure and the absence of nuclear atypia and 
a normal nuclear polarity. PanIN-2 show more papillary features and evidence of nuclear atypia 
and infrequent mitosis. PanIN-3 is also called carcinoma in situ. It shows a nearly complete loss 
of polarity and nuclear atypia as well as frequent mitosis (Koorstra et al. 2008). 
 
Figure 1; Pancreatic intraepithelial neoplasia (PanIN) progression and the corresponding mutations during early, 
intermediate and late changes of pancreatic ductal epithelium (Maitra et al. 2003) 
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Rudolf Virchow assumed that benign, inflammatory processes could lead to malignancy (Balkwill 
& Mantovani 2001). Since then, different reports confirmed Virchows assumption for different 
organ systems (Thun et al. 2004). Long standing inflammation of the pancreas, which is known 
as chronic pancreatitis (CP), is a major risk factor for PDAC, although not all CPs develop to PDACs 
(Lowenfels et al. 1993; Ekbom et al. 1994).  Chronic pancreatitis is defined through the loss of 
acinar cells, the occurrence of acinar-to-ductal metaplasia (ADM), leukocyte infiltration and 
replacement of stroma. The period until CP becomes pancreatic cancer can last up to two 
decades. For a long time, the link between CP and PDAC was not clear. Both diseases show 
similar histological features, except that PDACs occur with carcinoma cells (Logsdon & Ji 2009). 
Contrary to the initial assumption that PDACs arise from ductal cells, it was shown that PDAC 
and CP may both arise from acinar cells (Guerra et al. 2007) that undergo a formation evoked 
by the genetic instability and damage during constant inflammation (Brentnall et al. 1995; 
Maitra & Hruban 2008). It is known that all PDACs show areas of fibrosis as does CP, and that 
nearly all CPs contain early PanINs which possess mutations in KRas (Logsdon & Ji 2009; Volkholz 
et al. 1982; Löhr et al. 2005; Deramaudt & Rustgi 2005). 
It has been shown that Ras activity is upregulated in all PDACs (Almoguera et al. 1988; Ji et al. 
2009). Elevated Ras activation leads to extensive senescence of acinar cells and serious 
inflammation and fibrosis (Ji et al. 2009). Subsequently, additional spontaneous genetic 
alterations may occur, which again results in CP and PanINs (Maitra & Hruban 2008). Different 
studies have shown not only a mutated KRas gene is responsible for the progression of CP, 
PanINs and finally invasive carcinoma also additional factors are necessary for the development 
of PDAC. Ji et al. showed that pancreatic acinar cells transform by endogenous levels of mutated 
KRas only in combination with displaced tumor suppressor p53 (Ji et al. 2009). Others have 
shown that mutations in regulatory genes (e.g. p16), mucins,  and different inflammatory stimuli 
are needed in addition to mutated KRas for development of the full spectrum of CP and PanINs 
(Maitra et al. 2003; Guerra et al. 2007) (see also Figure 1). On the other hand, inflammatory 
stimuli are mediated by the combination of mutated KRas with TGF-α (Siveke et al. 2007). These 
findings suggest that KRas plays a key role in the progression of pancreatic cancer, but it is not 
the only actor during this multilayer process.  
 
 
1.2. Epithelial to Mesenchymal Transition 
The loss of adherent junctions and the change to a fibroblast-like morphology are typical for 
cancer cells. This change in cell shape and cell-cell and cell-extracellular matrix (ECM) 
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connections are embraced by the term epithelial to mesenchymal transition - EMT. EMT is a 
form of epithelial plasticity, where epithelial cells detach from their neighbors to acquire 
mesenchymal characteristics and become motile and invasive. Different molecular processes 
take part during the initiation of EMT and its completion. This includes the activation of 
transcription factors, the expression of certain cell-surface proteins, the reorganization and 
expression of cytoskeletal proteins, the production of ECM-degrading proteins, such as MMP3, 
and changes in the expression of certain miRNAs (Lee et al. 2012; Kalluri & Weinberg 2009). 
 
Figure 2; Overview of EMT 
Polarized epithelial cells expressing typical markers such as E-cadherin, Cytokeratin, and MUC1 undergo a transition 
to mobile mesenchymal cells expressing ECM components such as Snail, α-SMA, and Vimentin. During this process, 
cell-cell junctions are dissolved, a modification of the cytoskeletal structure leads to a change in cell shape from 
polygonal in spindly, and the cells detach from the basement membrane or destroy these by secreting inflammatory 
molecules. Assumed from Kalluri (Kalluri & Weinberg 2009) 
 
Physiologically, EMT is essential for embryonic development and enables the epithelium to form 
the mesoderm, the neural crest, and the heart valves (Nieto 2011). In adults EMT is needed for 
the branching of mammary ductal glands, wound healing, and tissue regeneration (Maier, Wirth, 
et al. 2010; Lee et al. 2012). However, EMT is also activated during organ fibrosis and tumor 
progression. Although the different types of EMT show many similarities in signaling pathways, 
regulators, and effector molecules, it is not clear which specific signals are responsible for the 
subdivision and the functional differences. Therefore, a classification into three subtypes, which 
was recommended by Kalluri and Weinberg in 2009 (Kalluri & Weinberg 2009), has since been 
widely addopted. Type I EMTs occur during the implantation of the embryo, the generation of 
germ layers during gastrulation, and the organ formation. This type of EMT can generate primary 
mesenchymal cells that can undergo MET to form secondary epithelia. The EMT associated with 
gastrulation is orchestrated by Wnt signaling, especially by Wnt3 and Wnt8c. A lack of Wnt3 
blocks the EMT during gastrulation (Liu et al. 1999). Conversely, an ectopic expression of Wnt8c 
leads to the formation of multiple primitive streaks (Pöpperl et al. 1997). 
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Figure 3; Different types of EMT 
Type I EMT is associated with embryogenesis and forms the mesoderm, endoderm and mobilizes neural crest cells. 
Primary mesenchyme built via EMT can be re-induced to undergo MET. 
Type II EMTs are associated with inflammation and fibrosis and can be expressed over a prolonged period. Due to 
inflammation, different molecules are generated by inflammatory cells and myofibroblasts (residential activated). 
This can lead to the degradation of the basement membrane, the loss of cell polarity, and the occurrence of either 
apoptosis (majority of cells) or EMT (minority). 
Type III EMTs occur after normal epithelial cells lost their polarity and detached from the basement membrane. The 
basement membrane changes its morphology resulting in the change of cell-EC; interactions and signaling networks. 
Only now does EMT take place to promote intravasation and extravasation. The formation of metastases may involve 
MET to allow the cells to get back to an epithelial phenotype.   Modified from (Kalluri & Weinberg 2009) 
 
Type II EMTs are associated with wound healing, tissue regeneration, and organ fibrosis. The 
EMT program begins as a repair program that normally generates fibroblasts and other related 
cells to reconstruct tissues following injury. The generated fibroblasts release different 
inflammatory signals as well as components of ECM such as collagens, laminins, and elastin 
(Kalluri & Weinberg 2009). Other recruited inflammatory cells such as macrophages can trigger 
EMT through the release of growth factors and chemokines. The epithelial cells influenced by 
these signals can lose their polarity and induce the damage of basement membrane (e.g. 
through MMP3), which is a main characteristic of EMT. This process can end in ongoing 
inflammation what again leads to organ fibrosis and eventually destruction. During chronic 
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inflammation the cells may display both epithelial morphology and molecular markers (E-cad, 
Cytokeratin), and expression of mesenchymal markers like α-SMA (Kalluri & Weinberg 2009). 
As described above, extensive proliferation, migration and invasion are hallmarks of cancer 
(Hanahan & Weinberg 2011). In different studies EMT has been suggested as a critical 
mechanism for these hall marks (Thiery et al. 2009). This type of EMT was termed by Kalluri and 
Weinberg as type III EMT. It only occurs in cells that have previously undergone genetic and 
epigenetic changes, which would lead to cancer progression and metastasis. Therefore it is not 
surprising that cells at the invasive tumor front undergo type III EMT (Thiery et al. 2009). These 
cells pass through the EMT program in different extents, so that some cells keep many epithelial 
properties and acquire just a few mesenchymal ones. Other cells lose all their epithelial behavior 
and become fully mesenchymal (Kalluri & Weinberg 2009). It is still unclear which specific signals 
induce type III EMT and which signals dictate the extent to which a cell undergoes EMT, but it is 
accepted that TGFβ plays a crucial role (Song 2007; Bierie & Moses 2006). Other studies have 
shown that metastasizing cancer cells not only undergo EMT, but also must undergo 
mesenchymal to epithelial transition (MET) when forming secondary tumors (termed 
metastasis) (Zeisberg et al. 2005). 
As mentioned before, TGFβ seem to play a key role during the initiation of type III EMT and might 
be the most important soluble EMT-inducer (Ikushima & Miyazono 2010). TGFβ is an important 
regulator of tissue homeostasis and has distinct roles during tumor development and 
progression. For example, it was shown that in cancer cells TGFβ can induce either apoptosis or 
survival associated with EMT. EMT is favored when TGFβ acts on activated Ras (Barrallo-Gimeno 
& Nieto 2005) because of the Ras-mediated stimulation of the RAF-MAPK pathway that appears 
to be necessary for EMT (Janda et al. 2002). In early tumor development TGFβ acts more as a 
tumor suppressor because of its inhibitory effect on tumor growth by the inhibition of MYC 
transcription factors and the induction of cell cycle inhibitors (Giehl et al. 2000). In later stages, 
tumor cells can overcome this suppression by becoming resistant to the cytostatic effect 
(Ellenrieder et al. 2001) and TGFβ acts as a promoter. Because there are rarely mutations in the 
TGFβ gene itself (Maitra & Hruban 2008), other pathways that mediate the effects of TGFβ must 
be affected. These include the MAPK/ERK pathway (Ellenrieder et al. 2001; Maier, Schmidt-
Strassburger, et al. 2010), the SMAD/STAT3 signaling (Zhao et al. 2008), and the activation of 
NFκB (Maier, Schmidt-Strassburger, et al. 2010). Mutations observed in the TGFβ signaling 
pathways are most often related to SMAD4 resulting in its inactivation in 55% of cases and poor 
prognosis for PDAC patients (Blackford et al. 2009). In SMAD4- PDACs other signaling pathways 
(e.g. NFκB signaling) must compensate for the loss of canonical TGFβ signaling.  
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A major point of EMT is the loss of E-cadherin and the associated loss of cell-cell contacts. 
Through its intracellular domains, E-cadherin is linked to many signaling pathway molecules 
which in turn can influence its loss (Berx & van Roy 2009; Heuberger & Birchmeier 2010). A 
prominent influencer is mutated KRas that leads to a loss of E-cadherin and an increase of 
Vimentin and ZEB1. This EMT-promoting transcription factor represses E-cadherin transcription 
directly through a NFκB-mediated up-regulation (Maier, Schmidt-Strassburger, et al. 2010). 
Therefore NFκB seem to be the most prominent factor to replace TGFβ-induced EMT in SMAD4 
deficient tumors (Fujioka et al. 2003; Maier, Schmidt-Strassburger, et al. 2010). Similar to ZEB1, 
Snail1 represses E-cadherin by binding directly to its promoter. In contrast, Twist indirectly 
represses the E-cadherin transcription (Peinado et al. 2007; Yang & Weinberg 2008). Another 
similarity between Snail1 and ZEB1 is the induction of MMP expression that can lead to the 
degradation of the basement membrane. MMP3 can trigger EMT by increasing the cellular levels 
of reactive oxygen species (ROS) which in turn induces Snail1 expression (Radisky et al. 2005). 
 
1.2.1. The role of Rac1b and MMP3 during EMT in pancreatic cancer 
Rac1 is a Rho-GTPase family member which can regulate actin organization, formation of 
filopodia, lamellipodia, and stress fibers (Ridley 2001; Boettner & Van Aelst 2002; Sahai & 
Marshall 2002). It also influences signaling pathways controlling gene expression and cell cycle 
progression (Schnelzer et al. 2000; Boettner & Van Aelst 2002). Rac1 cycles between its active 
(GTP-bound) and its inactive (GDP-bound) form. Different studies have not found mutations of 
Rac1 in different cancer types and cell lines, but overexpression on RNA and protein levels of a 
splice variant, designated Rac1b, has been described in breast and colon carcinomas (Schnelzer 
et al. 2000; Singh et al. 2004). This splice variant features an in-frame insertion of 19 additional 
amino acids behind the switch II domain of the normal Rac1 transcript (Schnelzer et al. 2000). 
The Switch domains are necessary for the conformational change during GDP-GTP-cycling 
(Vetter & Wittinghofer 2001). Due to the insertion, Rac1b shows a reduced downstream 
signaling compared to Rac1 and has an increased GDP-GTP-exchange leading to constitutive 
activation (Fiegen et al. 2004; Singh et al. 2004). The reduced ability to bind downstream 
effectors is apparent because Rac1b is not able to bind p21-activated kinase (PAK) or Jun NH2-
terminal kinase (JNK) (Matos et al. 2003). Rather it can hyper phosphorylate protein kinase B 
(known as AKT), increase ROS levels, and it retains the potential to activate NFκB (Singh et al. 
2004; Matos & Jordan 2005; Radisky et al. 2005). In mammary tumor cells Rac1b enhances the 
malignancy, genomic instability, MMP3-induced EMT, and motility (Radisky et al. 2005). In colon 
cancer cells it drives cell cycle progression (Matos & Jordan 2005). It was shown that Rac1b is 
expressed in vivo predominantly in pancreatic ductal epithelial cells and more in CP than in 
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PDAC. Rac1b expression was found in PDAC patients with a survival time over 24 months, 
whereas it was lacked in patients with poor outcome. (Ungefroren et al. 2014). Contrary to these 
findings, another study showed a specifically Rac1b expression in pancreatic tumor cells with a 
correlation to MMP3 expression. In the same study, distinct localization patterns were observed 
for Rac1b, which seem to be more associated with prognostic outcome than the expression 
levels (Mehner et al. 2014). Because of the ability of Rac1b to enhance motility and MMP3-
induced EMT, it was questioned as to its impact on TGFβ. According to the observation that 
Rac1b is highly expressed in longtime survivors, it was observed that Rac1b antagonizes the 
TGFβ-induced cell migration through the obstruction of SMAD3 phosphorylation and therefore 
the suppression of SMAD4 complex activation and function that results in a non-SMAD TGFβ 
signaling-mediated EMT. This was true in both malignant and non-malignant pancreatic ductal 
epithelial cells (Ungefroren et al. 2014). 
Through integrin activation, Rac1b can generate reactive oxygen species (ROS) by interaction 
with NADPH oxidase (NOX) (Hordijk 2006). An activation of Rac1b and therefore elevated ROS 
levels lead to DNA damage and genomic instability and therefore alterations in gene regulation, 
cellular morphogenesis, migration, and invasion (Kheradmand et al. 1998; Radisky et al. 2005). 
Radisky et al. found that Rac1b-associated ROS production is MMP3-dependent and leads to 
EMT-like morphology of SCp2 cells (Radisky et al. 2005). 
Matrix metalloproteinases (MMPs) are endopeptidases which are involved in nearly all 
biological processes: embryo implantation, mammary gland ductal branching, bone ossification, 
blood vessel remodeling, menstruation, wound healing, innate immune defense, cell death, and 
necrosis (Alexander et al. 1996; Vu & Werb 2000; Egeblad & Werb 2002; McQuibban et al. 2002). 
Due to its ability to degrade nearly every component of the ECM and the basement membrane, 
MMP activity is associated with the release of different ECM-bound proteins like VEGF and TGFβ. 
They are highly associated with chronic inflammation and cancer development, especially 
angiogenesis and tumor spread (Nagase & Woessner 1999; Overall 2002). MMPs are 
overexpressed in nearly all tumor types and they are involved in many stages of tumor 
progression (Radisky & Bissell 2006). They play an important role during invasion and metastasis 
because they also facilitate the degradation of cell adhesions, remodeling of the ECM, and 
intravasation and extravasation. Additionally, they are more and more considered to influence 
EMT (Orlichenko & Radisky 2008). Moreover, it was shown that MMP3 can induce EMT-
associated fibrosis and carcinogenesis in adult transgenic mice (Lochter et al. 1997) through the 
induction of genomic instability by disruption of the tissue homeostasis (Radisky & Bissell 2006).  
Notably, MMP3 is associated with the release of pro-angiogenic factors. It cleaves VEGF-binding 
proteins in the ECM or the VEGF-CTGF-complex (connective tissue growth factor) to release 
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active VEGF (Lee et al. 2005; Hashimoto et al. 2002). In endothelial cells MMP3 can cleave 
perlecan to detach the basic fibroblast growth factor (Whitelock et al. 1996).  In vivo MMP3 can 
cleave and release, and therefore activate, the heparin-binding EGF-like growth factor to 
promote angiogenesis (Suzuki et al. 1997). On the other hand, MMP3 can cleave off the NC1 
domain of collagen which leads to the release of endostatin which acts as an anti-angiogenic 
factor (Ferreras et al. 2000). During tumor development MMP3 positively affects invasion and 
metastasis by shedding of the soluble ectodomain of E-cadherin to  cleave adherence junctions 
and therefore disrupt cell-cell contacts (Lochter et al. 1997). 
As addressed previously, MMP3 can control cell division and proliferation by regulating the 
availability and activation/ inactivation of ECM-bound growth factors. For the release of latent 
TGFβ, MMP3 cleaves the TGFβ binding partner LTBP and degrades decorin (Imai et al. 1997; 
Maeda et al. 2002). During wound healing and tumor development, the cleavage of osteopontin 
is MMP3-mediated and results in enhanced cell adhesive and migratory properties (Agnihotri et 
al. 2001). Tumor cells have developed several mechanisms to block and evade the immune 
response. Some of these mechanisms are MMP-mediated and cytokines and chemokines are 
MMP-targeted to modulate the immunologic and inflammatory response. MMP3-cleavage of 
α1-proteinase inhibitor results in a reduced cytotoxic effect of natural killer cells (Kataoka et al. 
1999). MMP3 can release the Fas ligand from cell surface to bind to the Fas receptor and 
therefore lower its pro-apoptotic potency (Tanaka et al. 1998). Also it can process IL-1β to its 
biologically active form (Ito et al. 1996; Schonbeck et al. 1998). Due to an overexpression and 
dysregulation of MMP3 all of these points are essential for tumor development and progression, 
cell invasion and metastasis. Epithelial-associated MMP3 overexpression occurs in about 80% of 
pancreatitis patients (Bramhall et al. 1996). In normal, adult tissues MMP3 is expressed by 
fibroblasts at low levels and rises during wound healing and tumor development (Witty et al. 
1995; Stetler-Stevenson et al. 1996). Some studies showed that MMP3 overexpression is able to 
induce spontaneous tumor development in the lung and it is also linked to tumor development 
and progression in breast, colon, and cervical cancer (Stallings-Mann et al. 2012; Lochter et al. 
1997; Sternlicht et al. 1999). In pancreatic cancer it was shown that MMP3 is specifically 
expressed in pancreatic tumor cells with an association to Rac1b expression (Mehner et al. 
2014). As previously described by Mehner et al., the expression of MMP3 in different tumor 
stages implies a poor outcome in breast and lung cancer (Mehner et al. 2015). The same is true 
for pancreatic cancer and the expression of Rac1b. Here the localization in combination with the 
expression plays a role in the prognostic outcome. A diffuse cytoplasmic (baseline) expression 
and a cytoplasmic punctate polar (polar) expression show a better chance of survival than the 
cytoplasmic punctate apolar (apolar) expression of Rac1b. The apolar expression of Rac1b is also 
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associated with higher MMP3 expression levels, but seems to be independent of the tumor 
stage itself (Mehner et al. 2014). Transgenic mice expressing MMP3 and KRasG12V show increased 
Rac1b expression levels and a recruitment of macrophages that leads to fibrotic changes and 
primes a more stromal microenvironment. In pancreatic adenocarcinoma cell lines the 
expression of MMP3 results in a higher expression of Rac1b and activates an invasive phenotype 
(Mehner et al. 2014).  
A main function of MMP3 is to induce EMT. In addition to the typical EMT features of 
downregulation of epithelial and upregulation of mesenchymal markers, the MMP3-induced 
EMT is accompanied by the loss of colony formation ability, increased cell spreading, and 
increased lamellipodia formation due to the release of growth factors as described above. 
Different experiments have shown that the expression of Rac1b induces cell scattering, which is 
necessary for cell spreading. The cell spreading is independent of the Rac1b-induced ROS 
production and ROS-induced EMT can also occur without cell spreading. That implicates that 
MMP3-induced cell spreading occurs downstream of Rac1b, but maybe parallel to the EMT 
mediated by ROS (Nelson et al. 2008). Because during embryonic development MMP3 
expression does not result in pathological EMT, there must be some protective signals arising 
from the microenvironment of normal tissue. The structure of healthy tissue is softer and more 
balanced, fibrotic tissue shows a stiff matrix with fibroblasts and increased scattering of cells (De 
Rooij et al. 2005; Liu et al. 2010). A study by Lee et al. showed that cells cultured on soft 
substrates did not respond to MMP3 treatment, whereas MMP3 treatment on stiff substrates 
resulted in EMT-like effects (Lee et al. 2012). Because Rac1b is a downstream target of MMP3, 
they determined whether MMP3-induced Rac1b expression is dependent on substrates 
stiffness. The study showed that Rac1b levels were increased by MMP3 but independent of 
substratum rigidity. Contrariwise, the production of ROS and the Rac1b-induced cell spreading 
were only detected in cells cultured on stiff substrates. In soft, compliant substrates Rac1b 
cannot localize to the plasma membrane because of reduced β1-integrin-mediated adhesion. 
The expression of MMP3 can elevate this adhesion only in cells cultured on stiff substrates. 
Delocalization of Rac1b inhibited interaction of Rac1b and the NOX-complex component p67phox 
at the membrane  resulting in decreased levels of ROS and the block of EMT-induction (Lee et 
al. 2012). These findings suggest that the membrane localization of Rac1b is essential for its 
downstream signaling and EMT induction.  
The principles of EMT have been discovered in cell culture but it is not clear if the situation in 
vivo is comparable. Furthermore, EMT is a transient event and may only occur at the invasive 
front of tumors. Human tumor samples stained with HE fails to show an EMT-typical morphology 
with spindly cells or similar. Therefore, tissues are stained for established EMT markers such as 
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low E-cadherin expression, Vimentin expression, and a higher Snail, Twist, and ZEB1 and ZEB2 
expression. 
 
 
1.3.  Aim of project 
Previous studies have suggested that MMP3-induced phenotypic alterations are dependent on 
Rac1b but little is known about the molecular details of the cooperation of MMP3 and Rac1b. 
The goal of this thesis work was therefore to investigate whether the expression of MMP3 and 
Rac1b influences the EMT machinery and if an expression of MMP3 or Rac1b in context with 
KRasG12D expression drives chronic pancreatitis to PDAC. 
To define the molecular characteristics of MMP3- and Rac1b-induced EMT in vitro, the PDAC cell 
lines S2-007 and MiaPaCa, cultured on standard tissue plates or on plates coated with Matrigel, 
were to be analyzed. Treatment with recombinant MMP3 and adenoviral MMP3 and Rac1b to 
achieve overexpression was to be used to further investigate the influence on the expression 
and localization of the typical EMT markers E-cadherin and Vimentin. In addition, recombinant 
or adenovirus-expressed TGFβ was to be used as control in addition to untreated or AdGFP-
treated cells. 
To investigate a potential effect of MMP3 and Rac1b overexpression in vivo on the development 
of KRas-dependent PanINs and PDAC in the context of chronic pancreatitis, triple transgenic 
mice (rtTA-Ela1/tet-HA-MMP3/tet-KRasG12D; rtTA-Ela1/tet-YFP-Rac1b/tet-KRasG12D) were to be 
used as experimental model. The mice express either MMP3 or Rac1b under the control of the 
Elastase-1 promotor specifically in exocrine pancreatic acinar cells which are assumed to be cells 
of origin of PDAC. After defined treatment regiments mouse pancreata were to be dissected and 
examined by microscopy for ADM, PanINs and PDAC. Additionally, EMT markers (E-cadherin, 
Amylase, Smooth muscle actin, Cytokeratin 19) were to be investigated by 
immunohistochemistry and RT-qPCR. 
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2.  Material 
2.1.  Buffers 
10x PBS 
1.3 M  NaCl 
27 mM  KCl 
100 mM Na2HPO4 
100 mM KH2PO4 
 Adjust pH to 7.4; autoclave 
 
10x TBS 
100 mM Tris pH7.9 
1.5 M  NaCl 
 
1x TBS-T 
10% (v/v) 10x TBS 
0.5% (v/v) Tween 20 
 
Tris-EDTA 
0.5 M   EDTA solution 
10 mM  Tris pH 7.9 
0.05%   Tween 20 
 
Citrat buffer 
10 mM  Citric acid 
0.05%  Tween 20 
Adjust pH to 6.0 
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2.2. Commercial Solutions und Kits 
Table 1; Commercial Kits, their application and manufacturer 
Kit Name Application Manufacturer 
Invisorb DNA Extraction Kit DNA extraction Stratec 
PeqGOLD TriFast RNA extraction PeqLab 
RNase-free DNase Kit RNA extraction Quiagen 
RNeasy Mini Kit RNA extraction Quiagen 
RNA-to-cDNA Kit cDNA synthesis Thermo Scientific 
ABgene SYBR green RT-qPCR Mix Thermo Scientific 
AdEasy Purification Kit Virus purification Agilent 
AdEasy Viral Titer Kit Virus titration Agilent 
 
 
2.3. Media for Cell culture 
DMEM (Dulbecos modified eagle medium)   Biochrom 
RPMI (Roswell Park Memorial)      Biochrom 
FCS, Penicillin-Streptomycin, Trypsin     Gibco/Invitrogen 
 
Freezing medium 
30%  FCS 
10%  DMSO  
60%  DMEM/ RPMI 
 
 
2.4. Cell lines 
Table 2; Cell lines 
Name Origin Medium 
8988T Human pancreatic adenocarcinoma DMEM with 10% FCS and 
1% Penicillin-Streptomycin 8988S Human pancreatic adenocarcinoma 
Capan-1 Human pancreatic ductal adenocarcinoma 
RPMI with 10% FCS and 
1% Penicillin-Streptomycin 
HEK 293T Human embryonic kidney 
DMEM with 10% FCS and 
1% Penicillin-Streptomycin 
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IMIM Pc1 Human ductal pancreatic adenocarcinoma 
DMEM with 10% FCS and 
1% Penicillin-Streptomycin 
 
IMIM Pc2 Human ductal pancreatic adenocarcinoma 
MiaPaCa Human pancreatic carcinoma 
Panc1 Human pancreatic carcinoma 
S2-007 Human pancreatic carcinoma 
S2-028 Human pancreatic carcinoma 
 
 
2.5. Adenoviral vectors 
Table 3; Adenoviral vectors for cell line stimulation 
Vector name Virus name Titer MOI 
CMV-eGFP AdGFP 8 E6 IFU/ml 10 
CMV-p-TGFβ1 AdTGFβ 1.02 E9 IFU/ml 10 
CMV-r-MMP3 AdMMP3 2.7 E9 IFU/ml 10 
CMV-m-Rac1b AdRac1b 1.02 E9 IFU/ml 10 
 
All constructs are predicted on a recombinant human adenovirus type 5. The adenoviral vector 
AdGFP expresses enhanced green fluorescent protein (eGFP) under the control of a CMV 
promoter. Enhanced GFP is a GFP mutant with improved fluorescence and stability. 
Recombinant eGFP adenovirus serves as a control for other recombinant adenoviruses to 
normalize the effect of adenoviral infection. CMV-p-TGFβ is the control for adenoviral protein 
and EMT-mediator expression. 
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2.6. Antibodies 
Table 4; Antibodies for immunohistochemistry and immunofluorescence 
Antibody Species For use Company 
α-E-cadherin mouse 1:400 BD (#610181) 
α-Amylase rabbit 1:500 Santa Cruz (#sc-25562) 
α-SMA rabbit 1:1000 Abcam (#AB5694) 
α-CK19 rabbit 1:400 Abcam (#AB52625) 
α-Ki67 rabbit - Abcam (#AB15580) 
α-GFP rabbit 1:1000 Abcam (#AB6556) 
α-Vimentin goat 1:100 Abcam (#AB11256) 
Alexa Fluor488 α-goat  rabbit 1:200 Thermo Fisher (#A-11078) 
α-rabbit 2nd antibody goat 1:250  
α-mouse 2nd antibody rabbit 1:250  
 
 
2.7. Enzymes and Proteins 
DNAse I (20U/µl)       PeqLab/ Qiagen 
Benzonase (10ku)       Novagene, Merck Millipore 
recombinant TGFβ (2µg)     R&D Systems 
recombinant MMP3      kind gift from Mayo clinic 
 
 
2.8. Drugs and Chemicals 
Caerulein desulfated (5mg)    Bachem 
NaCl 0,9%         Braun 
Mounting Medium IHC     Roth 
ProLong Diamond Antifade    Applied Biosystems 
Mounting medium with DAPI    Thermo Fisher 
 
 
2.9. Standards 
BSA          AppliChem 
GeneRuler DNA Ladder 50bp    Fermentas 
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2.10. Oligo nucleotides 
All oligo nucleotides (primers) were used for PCR as well as for RT-qPCR.  
Table 5; Oligonucleotides used for PCR and RT-qPCR 
Primer Sequence in 5’– 3‘ 
HA-MMP3_rat_fwd CTA TCC GAG GTC ATG AAG AGC TA 
HA-MMP3_rat_rev GCC TGG AAA GTT CTC AGC TAT TT 
  
MMP3_human_fwd CCA GGC TTT CCC AAG CAA AT 
MMP3_human_rev CAC AGC ACA GGC AGG AGA AAA 
  
YFP_fwd ACG ACG GCA ACT ACA AGA CC 
YFP_rev TTG TAC TCC AGC TTG TGC CC 
  
YFP-Rac1b_fwd TGG ACA AGA AGA TTA TGA CAG ATT GC 
YFP-Rac1b_rev CCC TGG AGG GTC TAT CTT TAC CA 
  
Rac1b_human_fwd TAT GAC AGA TTA CGC CCC CTA TC 
Rac1b_human_rev CTT TGC CCC GGG AGG TTA 
  
RPLP0_human_fwd TGT CTC TCC TCA GTG ACA TCG T 
RPLP0_human_rev TCA GGG TTG TAG ATG CTG CC 
  
RPLP0_mouse_fwd CCT ATA AAA GGC ACA CGC GG 
RPLP0_mouse_rev ACG TTG TCT GCT CCC ACA AT 
  
Ecad_human_fwd CGA GAG CTA CAC GTT CAC GG 
Ecad_human_rev GGG TGT CGA GGG AAA AAT AGG 
  
Ecad_mouse_fwd CAA CGA TCC TGA CCA GCA GT 
Ecad_mouse_rev TGT ATT GCT GCT TGG CCT CA 
  
Vim_human_fwd CTG AAC CTG AGG GAA ACT AAT C 
Vim_human_rev GCA GAA AGG CAC TTG AAA GC 
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Vim_mouse_fwd GCT CCT ACG ATT CAC AGC CA 
Vim_mouse_rev CGT GTG GAC GTG GTC ACA TA 
  
Amylase_mouse_fwd CAG AGA CAT GGT GAC AAG GTG 
Amylase_mouse_rev ATC GTT AAA GTC CCA AGC AGA 
  
CK19_mouse_fwd CCT CCC GAG ATT ACA ACC ACT 
CK19_mouse_rev AGG GCT GTT CTG TCT CAA ACT 
  
GFP_fwd CCC CAA CGA GAA GCG CGA TCA C 
GFP_rev TTA CTT GTA CAG CTC GTC CAT 
  
TGFβ_fwd ACT GAG TGT CTA GGC TCC AG 
TGFβ_rev CCC TTC CTG CTC CTC ATG G 
 
 
2.11. Specialized software 
Time Lapse Analyzer (Huth et al. 2011)  
Leica Slide Path Gateway; Leica Image Scope 
Adobe Illustrator        
 
2.12. Hardware 
Autoclave            VX95; Systec 
Gel documentation device        Vilber 
Cell culture hood          Thermo Scientific 
Centrifuges           Eppendorf, Heraeus, Beckmann, BioSan 
Electrophoresis chamber        BioRad 
Heating block           Dri-Block DB3A; Techne 
Heating board           Heraeus 
Incubator Cell culture         Sonyo 
Microscope for IHC         DMIL LED; Leica 
Microscope for cell imaging       Axiovert 2000M; Zeiss 
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“Mr. Frosty” Freezing container      Thermo Scientific 
NanoDrop            ND-1000; NanoDrop Technologies 
PCR Maschine           Master cycler ProS ; Eppendorf 
Powersupplys           BioRad, Consort 
qPCR Maschine           Applied Biosystem 
Slide scanner           SCN400; Leica 
Water bath           TW 20; Julabo 
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3. Methods 
3.1. Cell line cultivation 
Cell lines were cultivated at 37°C and a CO2 concentration of 5%. For all cell lines DMEM with 
10% FCS and 1% Penicillin-Streptomycin is used. The different cell lines were cultured in a 
monolayer at the bottom of the culture flask. Because the cells should not overgrow each other, 
they were splitted frequently. The ratio depends on the cell line and its behavior of growth, but 
normally it lies between 1:5 and 1:20. 
First the cells were washed with 1x PBS and they were trypsinated afterwards for about 3 
minutes at 37°C. The effect of Trypsin is stopped by the addition of DMEM. The cells were 
centrifuged for 3 minutes at 1200 rpm. After resuspending the cells, they were seeded in the 
needed ratio. 
 
 
3.2. Freezing and thawing of human cell lines 
For freezing cell lines, a so called “Mr. Frosty” is used. This is a container, which is filled with 
100% isopropanol. It can be stored in a freezer and the temperature drops step wise to -80°C. 
This leads to a gentle freezing of the cells. For freezing the cells, a special medium was needed. 
It contains 60% DMEM, 30% FCS, and 10% DMSO. 
After washing and trypsinating the cells they were centrifuged for 3 minutes at 1200 rpm. The 
pellet was resuspended in an appropriate volume of freezing medium and is converted in a 
cryotube. The tubes were placed in the freezing container, which was stored in the -80°C freezer. 
After 24 hours, the tubes were carried in to a storage box at -80°C. 
To seed frozen cells again they were thawed quickly in a 37°C water bath. The whole number of 
cells was transferred into a tube filled with 10 ml DMEM (37°C).  This tube was centrifuged for 3 
minutes at 1200 rpm. The supernatant was discarded, and the cells were resuspended in 10 ml 
DMEM. The cells were seeded into a culture flask of appropriate size (e.g. 75cm²). 
 
 
3.3. Treatment of human cell lines with recombinant proteins 
To stimulate the cells with 50U recombinant MMP3 (rMMP3) and 2ng TGFβ (rTGFβ) respectively 
(gifts from Derek C. Radisky, Research Center Mayo Clinic, Jacksonville FL, USA), they were 
solved in protein-containing DMEM and seeded on 12-well plates at a density of 7x104 cells/ml 
for S2-007 and 8x104 cells/ml for MiaPaCa cells. The growth conditions differed from normal 
 20 Methods 
culture. Instead of 10% FCS only 1% was given to DMEM. Additionally, 1% Insulin-Transferrin-
Selenium-Ethanolamine (ITS-X) was included. The cells were cultured for 48hrs with the 
recombinant proteins bevor DMEM was changed and new rMMP3 or rTGFβ was added. 
In some experiments the cells were grown on Matrigel©. This simulates cells growing in vivo-like. 
The experiments were conducted under the same conditions as described above. 
 
3.4. Wound healing with and without treatment with recombinant protein 
The growth conditions were the same as described above. The cells were seeded in a bit higher 
concentration 24hrs prior treatment to grow till they were confluent. With a 10µl pipette tip, a 
wound was drawn into the cell layer and the cells were treated with the recombinant proteins 
as described above. The cells were monitored for 24h using a Zeiss Axiovert 2000M inverted 
microscope at 10X magnification. With differential interference contrast, one picture every 
10min was taken. The resulting time lapse movies (picture stacks) were analyzed using the "Time 
Lapse Analyzer" software (Huth et al. 2011). Time lapse recording and analysis was performed 
by the group of Malte Buchholz. 
 
 
3.5. Purification and titration of Adenovirus 
The transfection and all steps afterwards were done under S2 conditions. 
One day before the transfection HEK 293T cells were seeded in a concentration of 1*107cells per 
145cm² dish. 2.7*105 VP AdTGFβ and 1.6*105 VP AdRac1b were given to the cells and they were 
incubated for 5 days under normal growth conditions until most of the cell were detached. 
The purification was conducted with the AdEasy virus purification kit by Agilent technologies. 
First, the medium was transferred into a 50ml tube and centrifuged at 3 500 x g for 15min. A 
part of the supernatant was stored in a new tube at 4°C. The cell pellet is resuspended in 10ml 
of left supernatant and lysed by three freeze-and-thaw cycles. Afterwards, the suspension was 
centrifuged again at 3 500 x g for 15min. The supernatant was kept and added to the reserved 
supernatant. The DNA and RNA digestion with 12.5U Benzonase per 1ml supernatant was 
performed at 37°C for 30min. During this time, a tube set was attached to a 50ml syringe and 
the air was cast out of the syringe by drawing up and down some supernatant. The whole 
amount of supernatant was filtered through a 45µm filter into a sample container until 2ml were 
left. Nine parts of supernatant were attenuated with 1 part 10x loading buffer and the syringe 
was filled with it. A Sartobind unit was placed on the syringe and the supernatant was passed 
dropwise through it. The sample container was filled with the same volume of washing buffer 
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and passed through the sartobind unit until 2ml were left in the syringe. The Sartobind unit was 
transferred to a 10ml syringe, which was filled with 5ml elution buffer. A red solution tip was 
fixed at the outlet of the sartobind unit and 1ml elution buffer was passed very slowly through 
the unit. The supernatant is collected in a sterile 15ml tube. The left 4ml were incubated for 
10min and then also passed through very slowly. Finally, some air was pushed through the 
sartobind unit to get out as much elution buffer as possible. 
In the last step, a centrifuge concentrator was used to concentrate the virus to a suitable grade. 
The centrifugation at 3 000 x g is stopped when sample volume reaches 1ml. The flow through 
was discarded, 4ml of storage buffer were added, and the centrifugation step was repeated. The 
concentrated virus was resuspended, aliquoted, and stored at -80°C. 
One aliquot was used to determine the viral titer with the AdEasy viral titer kit. Therefor HEK 
293T cells were seeded in a 24-well plate with a concentration of 2*105 cells per well. The virus 
was diluted in a range from 10-2 to 10-6 with DMEM and 50µl of each dilution was added 
dropwise to two wells each. The cells were incubated for 48hrs at 37°C. Afterwards the medium 
was evacuated and the cells were dried for 10min at 37°C. To fix the cells, 500µl ice cold 100% 
methanol were added to each well and incubated for 10min at -20°C. The methanol was 
aspirated and the cells were washed twice carefully with 500µl 1xPBS containing 1% BSA. The 
mouse anti-hexon antibody was diluted 1:500 in 1xPS with 1% BSA, 250µl were added to each 
well, and incubated for 1hr at 37°C. The cells were washed twice carefully with 1xPBS containing 
1% BSA and 250µl of HRP-conjugated antibody – diluted in 1xPBS with 1%BSA – were added to 
each well. Again, the antibody was incubated for 1hr at 37°C. During this time a working solution 
of one part 10xDAB and 9 parts peroxide buffer was prepared. The cells were washed twice with 
1xPBS containing 1% BSA and 250µl DAB working solution were added. The incubation lasts until 
the cells become dark brown or black. The DAB was aspired and 250µl 1xPBS were added to 
each well. 
To calculate the titer, the well with about 10% positive stained cells was chosen and enumerated 
(10 fields in a 20fold magnification). The infection units (IFU) were calculated with the following 
formula: 
 
X =  ஺௩௘௥௔௚௘ ௡௨௠௕௘௥ ௢௙ ௖௘௟௟௦ ௣௘௥ ௙௜௘௟ௗ ∗ ௙௜௘௟ௗ ௣௘௥ ௪௘௟௟
௏௢௟௨௠௘ ௢௙ ௗ௜௟௨௧௘ௗ ௩௜௥௨௦ ௣௘௥ ௪௘௟௟ ௜௡ ௠௟ ∗ ௨௦௘ௗ ௗ௜௟௨௧௜௢௡ ௙௔௖௧௢௥
 
 
X =  ஺௩௘௥௔௚௘ ௡௨௠௕௘௥ ௢௙ ௖௘௟௟௦ ௣௘௥ ௙௜௘௟ௗ ∗ ଷଵସ ௙௜௘௟ௗ௦ (௚௜௩௘௡ ௙௢௥ ଶ଴௙௢௟ௗ ௠௔௚௡௜௙௜௖௔௧௜௢௡)
଴.଴ହ ௠௟ ∗ ௨௦௘ௗ ௗ௜௟௨௧௜௢௡ ௙௔௖௧௢௥
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3.6. Treatment of human cell lines with Adenovirus 
The appropriate volume of Adenovirus was added to standard-used DMEM with a MOI of 10, 
meaning 7*105 / 8*105 VP were needed for infection for a cell density of 7*104 cells/ml for S2-
007 and 8*104 cells/ml for MiaPaCa. The cells were seeded on 12-Well plates and cultured for 
48hrs at 37°C with 5% CO2. 
 
 
3.7. DNA preparation 
For the DNA preparation from mouse tail the Invisorb Spin Tissue Mini Kit is used. Before the 
preparation was started some buffers must be set up. To the binding buffer A 21ml pure 
Isopropanol and to the washing buffer 105ml of pure Ethanol were added. The Proteinase K tube 
was conducted with 2ml of nuclease free water. All components of the kit can be stored at room 
temperature accept the Proteinase K, which must be stored at -20°C. 
To each mice tail, 400µl Lysis Buffer G and 40 µl Proteinase K were added. The samples were 
mixed well and they were incubated over night at 52°C. 
On the next day at first an appropriate amount of Elution buffer was heated up to 52°C. The 
samples were centrifuged for 2min at 11 000 x g. The lysate was transferred into a 1.5ml reaction 
tube and 200µl Binding Buffer A were added and the sample is mixed well. The whole sample, 
but not more than 700µl, was converted to the DNA spin column, incubated for 1min and 
centrifuged for 2min at 11 000 x g. The flow-through is discarded. For washing the column twice, 
550µl Wash Buffer were added and the column was centrifuged for 1min at 11 000 x g. Both 
times the flow-through was discarded. To dry the column completely, the column was 
centrifuged for 4min at 15 000 x g. During the last preparation step, 200µl preheated Elution 
Buffer were added and incubated for 3 min at room temperature, and then the column is 
centrifuged for 1min at 11 000 x g. 
 
 
3.8. RNA preparation from human cells and tissue 
The preparation of RNA from human cells and mice tissue was conducted with PeqGOLD TriFast. 
The media was removed from the cells and an appropriate volume of PeqGOLD TriFast was given 
to the cells and they were detached by pipetting the solution up and down for several times. 
When RNA was conducted from mice tissue the tissue was crushed with a tissue mixer. The 
following steps were the same for cells and tissue. 
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The mixture was converted in to a 1.5ml reaction tube and incubated for 5min. Afterwards, it 
was possible to store the samples for a few months at -80°C or to go on with preparation of RNA. 
For the preparation 200µl Chloroform were added to the TriFast-mixture. After shaking well, the 
sample was incubated for 10min at room temperature and centrifuged for 5min at 12 000 x g. 
The colorless upper phase was taken and transferred in to a new 1.5ml reaction tube. The left 
two phases can be stored at -10°C for potential protein and DNA preparation. For precipitation, 
500µl Isopropanol were added and the sample was mixed well before it was incubated for 10min 
on ice. After a centrifugation step of 15 min at 12 000 x g the Isopropanol-supernatant was taken 
carefully. The left pellet was washed twice with 1ml 75% Ethanol. Therefor it was mixed and 
centrifuged for 10min at 12 000 x g. When the pellet was washed the second time it was dried 
for a few minutes, but it should not dry completely. This will downgrade the solubility of the 
RNA. To resolve the RNA pellet, 87.5µl preheated RNAse free water were used. 
Because there can be left some DNA at the sample a DNAse treatment and a subsequent 
cleaning were necessary. Therefore, the RNase-free DNase Kit and the RNeasy Kit from Quiagen 
were used. 
At first, the whole amount of the sample was given to 10µl RDD buffer which was shifted with 
1µl DNAse. To get an end volume of 100µl the sample was filled up with RNase-free water and 
incubated at room temperature for 10min. Afterwards 350µl RLT buffer were added and the 
samples was mixed well. The procedure was repeated with 250µl 100% Ethanol. Then the 
mixture was converted into a column with 2ml collection tube and centrifuged for 15sec at 
10000 x g. The flow-through was discarded, 500µl RPE buffer with Ethanol were given on the 
column, and the column was centrifuged for 15sec at 10 000 x g again. This washing step was 
repeated and after discarding the flow-through the column was transferred in to a new 2ml 
collection tube to centrifuge for 1min at full speed. Now the column was transferred into a 1.5ml 
collection tube and 40µl RNase-free water were added. Again a centrifugation step for 1min at 
full speed was conducted. The eluate was transferred to the column again and the centrifugation 
step was repeated. 
The concentration of the RNA was measured with the NanoDrop. Afterwards the RNA was 
stored on ice for usage or at -80°C for longtime storage. 
 
 
3.9. cDNA synthesis 
The cDNA was synthesized from mRNA by reverse transcription using the High Capacity RNA-to-
cDNA Kit from Applied Biosystems. The included RT Enzyme Mix contains Oligo dT primers and 
RNA-depending DNA-Polymerase (reverse transcriptase). 
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For the synthesis 1µg total RNA is used. The needed sample volume was calculated from the 
RNA measured concentration. 
V = 1µg/ cRNA 
The calculated sample volume was added to 10µl RT buffer and 1µl Enzyme Mix. With nuclease-
free water the sample was filled up to 20µl. All components were mixed and they were spine 
down to eliminate any bubbles. The reaction was incubated at 37°C for 60min, then stopped by 
heating up to 95°C for 5min, and at least cooled to 4°C. For convenience, the incubation was 
performed in a thermal cycler. The synthesized cDNA was diluted 1:10 with nuclease free water 
before it was used for RT-qPCR or stored at -20°C. 
 
 
3.10. Primer design for RT-qPCR and PCR 
For the following described PCR methods, short nucleotides called primers were needed. These 
primers were designed by myself. 
The NCBI reference number for your chosen gene was set in the NCBI primer blast tool. The 
product size should range between 120 and 160 base pairs and the melting temperature was 
set between 53°C and 63°C. The maximum temperature difference between the primer pairs 
was et to 1°C. The stringency of primer specificity was set to 4, 4, 4, and 9. NCBI Primer Blast 
gives out mostly more than one primer pair. Which one is the best was tested with two other 
primer design tools – Integrated DNA Technologies Oligo Analyzer and Primer3 Primer3Plus 
Interface. In both cases the primer sequences were supplied to the tool and different options 
were shown for the tested sequences. The hairpin stability, and the self and hetero dimerization 
were chosen as low as possible. The best fitting primer pairs were ordered by Biomers or 
Invitrogen. 
 
 
3.11. Polymerase Chain Reaction (PCR) – genotyping of mice 
First the template DNA is melted at 90 degrees. During the 30sec annealing period specific 
primers (see Table 5) bound to the template and be extended with the help of a Taq-Polymerase 
and nucleotides at the for the used primer appropriate temperature. The procedure was 
repeated 35 times, so that enough DNA was synthesized to show it on a 2%-agarose gel. 
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3.12. Real Time – quantitative Polymerase Chain Reaction (RT-qPCR) 
With this method, it is possible to quantify the relative expression of a target gene in relation to 
a reference gene like RPLP0.  
The used primers were complementary to the cDNA strand and they were designed to span 
exon-intron boarders so that they were specific for cDNA and not for genomic DNA, which could 
be still in the sample. For each sample a triplicate with respectively 6 µl cDNA were prepared. In 
addition, 19 µl of a master mix were added. This mix contains 1 µl of the appropriate primer pair 
(forward and reverse; 100 pmol/µl), 11.5 µl ABgene SYBR green PCR mix, and 8 µl double distilled 
water. After the activation of the hot-start polymerase for 15 min at 95°C, the PCR run through 
40 cycles of denaturing (95°C), annealing (60°C), and elongation (60°C). During the denaturing, 
the DNA double strand melts into its two single strands and the primers can bind to the single 
strands (annealing). The polymerase can bind to the 3’ end of the primer-DNA hybrid and can 
elongate it. 
The quantification is possible because the PCR mix contains the dye SYBR green, which only can 
intercalate between double stranded DNA. After each cycle the emission of SYBR green is 
measured and the amount of double stranded DNA is detected. At the end of the PCR, a melting 
curve is monitored to investigate the specificity of the amplification products. 
With the collected data, the average of the cycle threshold (CT) from one triplet was calculated. 
The CT is the PCR-cycle, of which the background fluorescence has significantly exceeded by the 
fluorescence of DNA-bound SYBR green. The CT of the investigated gene (sample) was 
normalized with the CT of the housekeeping gene (hkg) RPLP0.  
Normalization:     ∆CT  =  CT sample  –  CT hkg  
Aberration of ∆CT:     √((aberration sample)²  +  (aberration hkg)²) 
Comparison of conditions:  ∆∆CT  =  ∆CT control -  ∆CT treatment 
Relative expression:   x  =  2∆∆CT 
Error of relative expression: ∆x  =  √((x * ln2)² * aberration ∆CT²) 
The final result of the RT-qPCR was shown graphically in a bar chart.  
 
 
3.13. Mouse Handling 
Original adult transgenic mice were a generous gift from Derek C. Radisky. 
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3.13.1. Mating of breading and weaning of baby mice 
On a regular basis, it was controlled if the breeding mates got pups. If so, the breeding number, 
the birth date, and how many babies were born was documented. Three weeks later the pups 
were old enough to set an ear clip and to get some tail tissue for genotyping (see 3.7 and 3.11). 
At the same time the mice were seated into new cages. One cage contains up to six mice. Cages 
with male mice were named with A, C, E, etc. and cages with female mice were named with B, 
D, F, etc. Furthermore, the cages were labeled with the users’ name, the reference number, the 
breeding from which the mice derived, the number of mice which were contained in the cage, 
if they were male or female, and the day of birth. Additionally, the clip numbers of the mice 
were observed and if they get chow embedded with Doxycycline (Doxy chow). Initially, all mice 
get Doxy chow, the final decision for or against Doxy chow was made after the genotyping and 
classification in to the experimental groups. 
 
Classification 
After genotyping the mice, they were classified into different experimental groups. There should 
be six mice in each group, three males and three females. Ideally, they were not from the same 
breeding. 
Table 6; experimental classification of double and triple transgenic mice 
Genotype Experimental groups 
rtTA-Ela1/tet-HA-MMP3/tet-KRas 
- Doxycycline; + NaCl                 5 months, 5x week 
+ Doxycycline; + Caerulein        5 months, 5x week 
- Doxycycline; + Caerulein        5 months, 5x week 
rtTA-Ela1/tet-YFP-Rac1b/tet-KRas 
- Doxycycline; + NaCl                 5 months, 5x week 
+ Doxycycline; + Caerulein        5 months, 5x week 
- Doxycycline; + Caerulein        5 months, 5x week 
The grouped mice should be between 6 and 8 weeks old, the age difference should not be higher 
than one week.  
 
3.13.2. Treatment with Caerulein 
Before starting the experiments, the used Caerulein must be tested. Therefore, wild type mice 
were splattered eight times each hour (8x a day). After two days, they were killed and the 
pancreas was dissected out as described below. When the organ shows pancreatitis, the 
Caerulein flask can be used for the experiments. 
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As described above the experiments last 20 weeks (5 months). During this time, the mice were 
splattered each day on the left side with 100µl of 0.05µl Caerulein or physiological NaCl, 
depending on experimental group. It was important to splatter intraperitoneal and not subcutan 
to guaranty that the solution reaches the pancreas. By male mice it was also important not to 
splatter to close at the sexual organs, because than they can develop an inflammation of the 
penis, what can lead to death. In case of redness and hardening of the skin, it was possible to 
splatter with caution on the right side of the mouse. 
 
3.13.3. Euthanizing of mice and organ removal 
After 5 months of experimental time, the mice were put to death by cervical dislocation after 
they have been sedated with 20mg per kg body weight Ketanest. The body was opened and the 
pancreas was dissected. It was divided by cutting into four pieces (each two pieces of pancreatic 
head and tail) and one part of the head and tail were carried into paraformaldehyde for IHC the 
other parts was transferred in to trizol for RNA preparation. Afterwards, other organs such as 
liver, kidney, or lung were dissected. 
 
 
3.14. Immunohistochemistry 
For every immunohistochemically staining paraffin sections were used. Therefor it was 
important not to allow the slides to dry at any step during the staining procedure. 
 
3.14.1. Hematoxylin Eosin staining 
A standard staining procedure for paraffin sections is the Hematoxylin-Eosin (HE) staining. 
For this method, the slides were deparaffinized and dehydrated for 10min in Xylene, afterwards 
for 5min in 100% Ethanol and then 2min each in 80% and 70% Ethanol. Then the slides were 
washed two times for 5min in deionized water. 
 
3.14.2. Antibody staining 
For the E-cadherin, the Amylase, the SMA and the CK 19 antibodies a protocol according to Cell 
Signaling was used. Ki67 was stained by Dr. Ramaswamy according to a protocol likely to the 
following one. The deparaffination and rehydration steps were the same as described above. 
For the staining with antibodies it is necessary to unmask the epitopes which should be 
recognized by the current antibody.  
For unmasking with 10 mM sodium citrate buffer at pH 6.0(α-Amylase, α-SMA) the slides were 
maintained at a sub-boiling temperature for 10 minutes in the microwave. The slides were 
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cooled down on ice for 20 minutes. For unmasking in 1 mM EDTA at pH 8.0(α-E-cadherin, α-
CK19) the slides were boiled in the microwave for 15 minutes at a sub-boiling temperature. No 
cooling was necessary and the slides were left on the bench top for 20min. 
The sections were washed in dH2O three times for 5min each, followed by incubating them in 
3% hydrogen peroxide for 10min. This step was necessary to block the endogenous peroxidase. 
Afterwards they were washed two times for 5min each in distilled water. The slides were 
transferred into a wet chamber and the tissue was circled with a DAKO Pen to provide a barrier 
to liquids applied to the sections. Each section was blocked with 200µl 10% BSA for 60min at 
room temperature. After removing the blocking solution, 200µl primary antibody, diluted in 
DAKO background reducing antibody diluent, was added to each section. They were incubated 
overnight at 4°C. The antibody solution was removed and the sections were washed three times 
in PBST for 5min each. The biotinylated secondary antibody, diluted 1:250 in PBST with 1% BSA, 
was added to each section and incubated for 60min at room temperature in the wet chamber. 
The ABC reagent was prepared 30min before use and incubated at room temperature. After 
removing the secondary antibody solution, the slides were washed three times with PBST for 
5min each. 200µl ABC reagent was added to each section and they were incubated for 60min at 
room temperature in the wet chamber. The slides were washed three times in PBST for 5min 
each. Then, 200µl DAB were added to each section and the staining to brown is monitored 
closely. As soon as the sections develop, they were immersed in distilled water. The slides were 
counterstained in hematoxylin for 20sec and then blued in tapped water for 5min. At least the 
sections were dehydrated. Therefor they were incubated 2min each in 70% and 80% ethanol 
followed by 5min in 100% ethanol and 10min in xylene. Then they were mounted. 
For the GFP antibody, a protocol given by our cooperation group at the mayo clinic was used. 
This protocol is executed in one day. The steps from deparaffination up to unmasking the 
antigen were the same as described above. Blocking the sections was done with serum-free 
protein block by DAKO for 5min at room temperature. The primary antibody was diluted 1:1000 
in background reducing reagent and incubated for 60min at room temperature in the wet 
chamber. After washing the slides three times in PBST the secondary antibody (anti rabbit; 
1:250) was incubated for 30min at room temperature in the wet chamber. Again, the slides were 
washed three times for 5min each in PBST and the ABC reagent was incubated for 30min. All 
remaining steps from incubating with DAB up to dehydrate and mount the sections were the 
same as described above. 
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3.14.3. Picrosirius Red staining 
The slides were deparaffinized and hydrated as described above, then they were stained in 
Weigerts Hematoxylin solution for 4min. To get shot of dispensable dye the slides were rinsed 
in distilled water for 10min. They were placed in Solution A (phosphor molybdic acid) for 2min 
and rinsed in distilled water till the water remains clear. The slides were placed in Solution B 
(Picrosirius Red) for 60min and then directly in to Solution C (HCl) for 2min. At least, the slides 
were dehydrated and mounted. 
Under polarized light the staining with Picrosirius Red shows different collagen types in different 
colors. The fibrils of type I were stained yellow and type III collagen is stained green.  
 
3.15. Immunofluorescence Staining 
For this staining method cells were used. They were seeded in an appropriate amount in 4-
chamber slides, treated or not, and then incubated for 72h under normal growth conditions. All 
following steps were performed with the chamber left on the slides. First the cells were washed 
with PBS, and then fixed with 4% Paraformaldehyde for 10min at room temperature. To make 
the cell membrane more permeable, they were washed with PBS and incubated with 0.2% 
Triton-X on ice for 2min. After washing with PBS, a blocking step with 1µg/µl BSA in PBS was 
performed for 15min at room temperature. The chambers were rinsed with 0.3% Triton-X bevor 
the primary antibody – diluted in PBS with 1.5% BSA – was incubated for 60min at room 
temperature. Washing three times PBS for 10min is followed by a washing step with 0.3% Triton-
X for 10min, bevor the secondary antibody was incubated for 60min at 37°C in the dark. The 
chamber is removed from the slide and the washing steps were repeated. The slide was 
mounted with ProLong Diamond Antifade Mountant, which already contains DAPI. The slides 
had to dry for 24hrs in the dark bevor they were monitored. 
 
 
3.16. Statistics 
The calculations of relative expression after RT-qPCR were performed as described in 3.12. 
The analyses of wound healing experiments were performed by the group of Dr. Buchholz using 
the Time Lapse Analyzer software (Huth et al. 2011). 
Ki67 positive cells were counted by hand vie Leica Image Scope Software. 
All statistical analysis was performed with Microsoft Office Excel 2016.  
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4. Results 
4.1. In vitro experiments with PDA cell lines 
4.1.1. Endogenous expression of Rac1b differs in PDAC cell lines 
To determine which PDAC cell lines were the most promising for further experiments, the 
endogenous expression of Rac1b and MMP3 was investigated by RT-qPCR. All cell lines used had 
an expression for MMP3 of not detectable (data not shown). Rac1b expression varied between 
cell lines, with the highest expression (8988S) measuring approximately 7fold higher than in the 
lowest expressing cell line (IMIM Pc2) (Figure 4). Cell lines marked with an arrow (S2-007, S2-
028 and MiaPaCa) were chosen for further experiments based on high expression of Rac1b, and 
their growth characteristics. Although 8988S cells showed the highest Rac1b expression they 
were excluded due to a slow and unsteady growth under regular culture conditions. Instead of 
them, S2-028 cells were chosen because they represent a less invasive clone of the originally 
Suit2 cell line. Oppositional to the high invasive clone S2-007 it would be interesting which 
behavior both cell lines would show after a potential EMT-induction. 
  
Figure 4; Expression of Rac1b compared to RPLP0 in pancreatic ductal adenocarcinoma (PDAC) cell lines 
In Panc1, S2-007, S2-028, 8988S, MiaPaCa, IMIM-Pc1, and IMIM-Pc2 cells the endogenic expression of Rac1b was 
investigated by RT-qPCR and was normalized to the housekeeping gene RPLP0. Cell lines marked with arrows were 
used for further experiments. 
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4.1.2. Treatment with recombinant MMP3 elevates wound healing rate in S2-007 cells 
The wound healing experiments were performed in cooperation with the group of Dr. Malte 
Buchholz. For the above outlined reasons, S2-007 and S2-028 cells were cultured on standard 
tissue culture plates and were either treated with 50U rMMP3 or not. After screening for 24hrs 
with a Zeiss Axiovert 2000M microscope the data were analyzed with the TimeLapseAnalyzer 
(Huth et al. 2011) and the wound healing rate of untreated cells was compared to treated ones. 
In S2-007 cells the wound healing rate increased after treatment with rMMP3 (Figure 5A), 
whereas in S2-028 cells the wound healing rate was nearly the same in both conditions (Figure 
5B). This is most likely due to the higher invasiveness of S2-007 cells compared to S2-028 cells. 
The S2-028 cells show congenitally low replication and migration rates, which seems to be 
unaffected by the potentially MMP3-mediated EMT activation. Therefore, the following 
experiments were performed only with MiaPaCa and S2-007. 
 
Figure 5; Rate of wounding in S2-007 and S2-028 cells after treatment with recombinant MMP3 
A) S2-007 cells were cultured on standard tissue culture plates and treated with 50U rMMP3. 
B) S2-028 cells were cultured on standard tissue culture plates and treated with 50U rMMP3. 
Untreated cells were used as control. The replication and migration of cells were screened for 24hrs with 
the Zeiss Axiovert 2000M and the analysis was performed with TimeLapseAnalyzer (Huth et al. 2011) in 
cooperation with the group of Dr. Malte Buchholz. 
 
 
4.1.3. Cells change their growth characteristics when cultured on Matrigel  
S2-007 and MiaPaCa cells were cultured under two different substrate conditions. On the one 
hand, they were cultured on standard tissue culture plates (Plastic) and on the other hand they 
were cultured on Matrigel-coated tissue culture plates (Matrigel). Under both conditions, they 
were either treated with recombinant proteins (Figure 6) or with adenoviral constructs ( Figure 
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7). AdGFP was used as a control for a potential effect of adenoviral treatment. TGFβ was used 
as an EMT-inducing control. 
Untreated S2-007 and MiaPaCa cells cultured on plastic showed typical mesenchymal growth 
characteristics with a spindle-like shape of the cells, a development of a cell monolayer without 
developing cell-cell contacts, and limited migration potential. On Matrigel, which mimics the 
extracellular environment and the basement membrane, S2-007 developed more epithelial 
growth characteristics. The cells lose the spindle-like appearance, show more branching, and 
grew in a net-like manner. Treated with rTGFβ or rMMP3, the cells seem to grow denser than I 
untreated cells, due to a higher proliferation and migration rate (Figure 6 left side). MiaPaCa 
cells did not show a net-like growth behavior when cultured on Matrigel. The cells became more 
rounded, but they did not show branching, they grew from doublets to clusters instead, which 
does not correlate to the classical epithelial growth behavior (Figure 6 right side). In untreated 
MiaPaCa cells the clusters were smaller and more doublets were observed than in protein-
treated ones, where MiaPaCa cells treated with rMMP3 grew in larger clusters than after rTGFβ 
treatment. 
 
Figure 6; Morphological changes in S2-007 and MiaPaCa cells after treatment with recombinant proteins on 
Plastic and Matrigel 
S2-007 and MiaPaCa cells were cultured on plastic and on Matrigel-coated tissue culture plates. They were treated 
with 2ng rTGFβ and 50U rMMP3 for 48hrs, untreated cells were used as controls and rTGFβ was used as an EMT-
inducing control. 
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Figure 7; Morphological changes in S2-007 and MiaPaCa cells after treatment with adenoviral constructs on 
Plastic and Matrigel 
S2-007 and MiaPaCa cells were cultured on plastic and on Matrigel-coated tissue culture plates and treated with 
AdGFP, AdTGFβ, AdMMP3, and AdRac1b for 48hrs with an MOI of 10. Cells treated with AdGFP were used as controls 
and AdTGFβ was used as an EMT-inducing control. 
When S2-007 cells were grown on Matrigel and treated with adenoviral constructs, the cells 
became more rounded and the net-like growth pattern changed to clusters. The clusters in 
AdTGFβ treated S2-007 cells were larger than in AdGFP, and even larger in AdMMP3 and 
AdRac1b treated cells, whereas there were no visible differences between AdMMP3 and 
AdRac1b treatment ( Figure 7 left side). When MiaPaCa cells were cultured on Matrigel and 
treated with adenoviral constructs they did not change their growth behavior and formed 
clusters again. In cells treated with AdGFP the clusters were the smallest compared to those 
with AdTGFβ, AdMMP3, and AdRac1b. Under these conditions the cells did not show visible 
differences in growth behavior ( Figure 7 right side). Because Matrigel mimics the basement 
membrane, it is comprehensible that cells cultured on Matrigel show an epithelial growth 
behavior like they would do in vivo. Further experiments will be conducted to investigate 
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whether the molecular machinery is influenced by the treatment with recombinant protein or 
adenoviral constructs, and if there are evidences for an induction of EMT. 
 
 
4.1.4. Adenoviral treatment elevates expression levels of GFP, TGFβ, MMP3, and Rac1b 
Adenoviral treatment is a reliable method to induce overexpression of a particular protein. The 
adenoviral constructs used for TGFβ, MMP3, and Rac1b were provided by Prof. Derek C. Radisky 
(Mayo clinic, Florida; Lee et al. 2012) and the construct for GFP was obtained from Vector 
BioLabs (see 2.5). AdGFP is a non-targeting vector for the normalization of adenoviral effects 
and AdTGFβ is the control for EMT-inducing pathways. 
To confirm that the adenoviral constructs used were working effectively, the relative expression 
of the related protein was investigated by RT-qPCR. S2-007 and MiaPaCa cells were cultured on 
standard and on Matrigel-coated tissue culture plates and treated with AdGFP, AdTGFβ, 
AdMMP3, and AdRac1b with a MOI of 10. For S2-007 cells, the expression of GFP after AdGFP-
treatment on plastic was elevated about 60fold compared to the treatment with AdTGFβ, 
whereas the elevation of GFP expression after treatment on Matrigel was much weaker (Figure 
8; Activation of GFP, TGFβ, MMP3 and Rac1b overexpression in S2-007 cells after treatment with 
the related adenoviral construct on Plastic and MatrigelFigure 8A). The expression of TGFβ after 
adenoviral treatment on Plastic and Matrigel gained, but showed the same pattern as it was 
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found for GFP. The expression after treatment on Matrigel was much weaker ( 
 
Figure 8B). The same is true for the activation of MMP3 and Rac1b over expression. After 
treatment on Plastic the expression of MMP3 and Rac1b was clearly elevated (Figure 8C and D), 
even significantly for MMP3, but after treatment on Matrigel there was just a slightly elevation 
of MMP3 expression (Figure 8C). An exception was the expression of Rac1b after treatment on 
Matrigel, here the expression was significantly elevated compared to the treatment with AdGFP 
(Figure 8D). But it must be pointed out that the treatment with AdGFP resulted in an elevation 
of Rac1b expression in both cell lines, but even more for S2-007 (Figure 8D and Figure 9D). 
Also for MiaPaCa cells it become apparent that treatment with adenoviral constructs on Plastic 
caused a clear elevation of the related proteins, even significantly for MMP3 again (Figure 9C), 
whereas the adenoviral treatment on Matrigel did only lead to a slightly elevation of expression 
(Figure 9). 
Though the results were fluctuating, they were reproducible and they show that the infection 
with AdGFP, AdTGF, AdMMP3, and AdRac1b results in overexpression of the related protein in 
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S2-007 and MiaPaCa cells on Plastic. Although adenoviral GFP, TGFβ, MMP3, and Rac1b 
treatment on Matrigel was not that efficient, all constructs were used under both culturing 
conditions to investigate, if an overexpression of MMP3 and Rac1b influences the expression of 
the typical EMT markers E-cadherin and Vimentin.  
 
  
Figure 8; Activation of GFP, TGFβ, MMP3 and Rac1b overexpression in S2-007 cells after treatment with the 
related adenoviral construct on Plastic and Matrigel 
S2-007 cells were cultured on standard and Matrigel-coated tissue culture plates and treated with adenoviral 
GFP, TGFβ, MMP3 and Rac1b. The expression of the respective protein was investigated by RTq-PCR and the 
expression was normalized to RPLP0. 
A) After AdGFP treatment the expression of GFP was investigated compared to treatment with AdTGFβ. 
B) After AdTGFβ treatment the expression of TGFβ was investigated compared to treatment with AdGFP. 
C) After AdMMP3 treatment the expression of MMP3 was investigated compared to treatment with AdGFP. 
D) After AdRac1b treatment the expression of Rac1b was investigated compared to treatment with AdGFP. 
* Symbolizes significance (p≤0.05) 
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Figure 9; Activation of GFP, TGFβ, MMP3 and Rac1b overexpression in MiaPaCa cells after treatment with the 
related adenoviral construct on Plastic and Matrigel 
MiaPaCa cells were cultured on standard and Matrigel-coated tissue culture plates and treated with adenoviral 
GFP, TGFβ, MMP3 and Rac1b. The expression of the respective protein was investigated by RTq-PCR and the 
expression was normalized to RPLP0. 
A) After AdGFP treatment the expression of GFP was investigated compared to treatment with AdTGFβ. 
B) After AdTGFβ treatment the expression of TGFβ was investigated compared to treatment with AdGFP. 
C) After AdMMP3 treatment the expression of MMP3 was investigated compared to treatment with AdGFP. 
D) After AdRac1b treatment the expression of Rac1b was investigated compared to treatment with AdGFP. 
* Symbolizes significance (p≤0.05) 
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4.1.5. Overexpression of MMP3 influences endogenous Rac1b expression 
Before investigating the expression levels of E-cadherin and Vimentin as representative EMT 
markers, it was of interest to analyze the influence of MMP3 overexpression on endogenous 
Rac1b expression levels. 
The expression of Rac1b was slightly influenced by treatment with recombinant MMP3. 
Compared to the expression in untreated cells, Rac1b levels rose about 2fold after rMMP3 
treatment, whereas the expression of Rac1b drops after treatment with the EMT-inducing 
control, rTGFβ (Figure 10A). After treatment on Matrigel, the expression of Rac1b drops again 
in rTGFβ- and was nearly doubled in rMMP3-treated cells (Figure 10B). The treatment with 
adenoviral constructs seem to have a contrary effect on the expression of Rac1b. Both, after 
treatment with AdTGFβ and AdMMP3 the expression of Rac1b seem to drop about 3fold on 
Plastic and even more on Matrigel (Figure 10C and D). It must be pointed out, that AdGFP 
treatment, what should have no effect on Rac1b expression, elevates the expression especially 
on Plastic. 
Similar results were obtained in MiaPaCa cells. The treatment with recombinant TGFβ and the 
treatment with AdTGFβ and AdMMP3 lowers the expression of Rac1b as it was seen for S2-007 
cells before (Figure 11). Other than in S2-007 cells the treatment of MiaPaCa cells with rMMP3 
also led to a drop of Rac1b expression compared to untreated cells (Figure 11A and B). 
The exogenous overexpression of Rac1b did elevate the endogenous MMP3 expression about 
25fold in S2-007 and in MiaPaCa cells compared to untreated cells, when cultured on Plastic. 
The results could not be confirmed for Matrigel and the treatment with adenoviral constructs 
(Figure 11C and D). The results indicate that there might have been a problem with the TGFβ 
control. Nevertheless, all the collected data seem to verify that Rac1b is a downstream target of 
MMP3 as described in literature (Nelson et al. 2008; Lee et al. 2012). 
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Figure 10; Expression of Rac1b in S2-007 cells after treatment with recombinant protein and adenoviral 
constructs 
A) S2-007 cells were cultured on standard tissue culture plates and treated with 2ng rTGFβ and 50U rMMP3. 
B) S2-007 cells were cultured on Matrigel-coated tissue culture plates and treated with 2ng rTGFβ and 50U 
rMMP3. 
C) S2-007 cells were cultured on standard tissue culture plates and treated with AdGFP, AdTGFβ, and AdMMP3 
(MOI=10). 
D) S2-007 cells were cultured on Matrigel-coated tissue culture plates and treated with AdGFP, AdTGFβ, and 
AdMMP3 (MOI=10). 
Untreated cells and AdGFP treated cells were used as controls, respectively. The expression of Rac1b was normalized 
to the expression of RPLP0. * Symbolizes significance (p≤0.05) 
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Figure 11; Expression of Rac1b in MiaPaCa cells after treatment with recombinant protein and adenoviral 
constructs 
A) MiaPaCa cells were cultured on standard tissue culture plates and treated with 2ng rTGFβ and 50U rMMP3. 
B) MiaPaCa cells were cultured on Matrigel-coated tissue culture plates and treated with 2ng rTGFβ and 50U 
rMMP3. 
C) MiaPaCa cells were cultured on standard tissue culture plates and treated with AdGFP, AdTGFβ, and 
AdMMP3 (MOI=10). 
D) MiaPaCa cells were cultured on Matrigel-coated tissue culture plates and treated with AdGFP, AdTGFβ, and 
AdMMP3 (MOI=10). 
Untreated cells and AdGFP treated cells respectively, were used as control. The expression of Rac1b was normalized 
to the expression of RPLP0. * Symbolizes significance (p≤0.05) 
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4.1.6. EMT induction depends on the used cell lines and the way of protein expression 
To find out whether the treatment with recombinant or adenoviral MMP3 and Rac1b and/or the 
matrix dependent morphological changes influenced the expression of EMT markers, S2-007 
and MiaPaCa cells were treated with both recombinant proteins and adenoviral constructs on 
plastic and on Matrigel. The expression of E-cadherin and Vimentin was examined by RT-qPCR 
and normalized to RPLP0. When S2-007 cells were treated with recombinant proteins, there 
seem to be no effect on the EMT-machinery. The treatment on Plastic as well as on Matrigel 
results in all cases in a higher E-cadherin than Vimentin expression (Figure 12), what indicates 
an epithelial cell behavior. The growth pattern seen under the microscope was convenient to 
this (Figure 6 and  Figure 7; left side). 
Adenoviral treatment on Plastic and on Matrigel showed elevated Vimentin and lowered E-
cadherin expression levels for AdTGFβ, AdMMP3, and AdRac1b compared to the treatment with 
AdGFP (Figure 12C and D). Although, under standard culturing conditions (Plastic), all three 
constructs showed an elevation of E-cadherin expression compared to AdGFP treatment, the 
Vimentin expression was even more elevated, whereat the treatment with AdRac1b showed the 
highest effect. Here the Vimentin expression was elevated about 2000fold compared to AdGFP 
treatment (AdTGFβ: 19fold; AdMMP3: 323fold). After treatment on Matrigel the E-cadherin 
expression was only elevated after AdRac1b treatment, compared to AdGFP (Figure 12D). 
Nevertheless, the Vimentin expression was higher after treatment with AdTGFβ, AdMMP3, and 
AdRac1b, compared to treatment with AdGFP. The highest Vimentin expression (277 500fold) 
was found after AdRac1b treatment again. AdTGFβ showed an elevation of 4.5fold and AdMMP3 
showed an elevation of Vimentin expression of 37fold. These results indicate that Rac1b seem 
to play a crucial role during EMT-induction, but it also seems not to be influenced by MMP3 and 
TGFβ as much as supposed. 
The same experiments as described above were performed for MiaPaCa cells. In this cell line the 
expression of E-cadherin and Vimentin was affected when cells were cultured on Plastic and 
treated with recombinant proteins (Figure 13A). Both, after rTGFβ and rMMP3 treatment the 
expression of E-cadherin was doubled compared to the expression in untreated cells but also 
the Vimentin expression was elevated 1.3fold for rTGFβ and 3.3fold for rMMP3, compared to 
untreated cells (Figure 13A). When the cells were cultured on Matrigel and treated with rTGFβ 
the E-cadherin expression was elevated about 6fold, whereas the E-cadherin expression after 
rMMP3 treatment was nearly the same, compared to untreated cells (Figure 13B). The Vimentin 
expression was highest in untreated cells and was about the half after treatment with 
recombinant protein. The treatment of MiaPaCa cells with adenoviral constructs showed the 
highest Vimentin expression levels after AdRac1b treatment (1 300fold and 27fold, compared 
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to AdGFP), as seen in S2-007 cells too (Figure 13C and D). Exception were the treatment with 
AdTGFβ and AdMMP3 on Plastic, here the Vimentin expression levels were lower than the E-
cadherin expression levels (Figure 13C). Nevertheless, in most cases of treatment (recombinant 
protein and adenovirus, Plastic and Matrigel) the Vimentin expression was higher than the E-
cadherin expression, what indicates that MiaPaCa cells show a naturally mesenchymal growth 
behavior, what might explain about the untypically growth pattern shown by MiaPaCa cells 
under the microscope (Figure 6 and  Figure 7; right side). 
 
 
Figure 12; Expression of E-cadherin and Vimentin in S2-007 cells after treatment with recombinant proteins and 
adenoviral constructs 
A) S2-007 cells were cultured on standard tissue culture plates and treated with 2ng rTGFβ and 50U rMMP3. 
B) S2-007 cells were cultured on Matrigel-coated tissue culture plates and treated with 2ng rTGFβ and 50U rMMP3. 
C) S2-007 cells were cultured on standard tissue culture plates and treated with AdGFP, AdTGFβ, AdMMP3, and 
AdRac1b (MOI=10). 
D) S2-007 cells were cultured on Matrigel-coated tissue culture plates and treated with AdGFP, AdTGFβ, AdMMP3, 
and AdRac1b (MOI=10). 
Small inserted graphs are detailed views of the lower bars, which do not appear well in the normal graph. 
Untreated and AdGFP treated cells respectively were used as controls. The expression of E-cadherin and Vimentin 
was normalized to the expression of RPLP0. * Symbolizes significance (p≤0.05) 
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Figure 13; Expression of E-cadherin and Vimentin in MiaPaCa cells after treatment with recombinant proteins and 
adenoviral constructs 
A) MiaPaCa cells were cultured on standard tissue culture plates and treated with 2ng rTGFβ and 50U rMMP3. 
B) MiaPaCa cells were cultured on Matrigel-coated tissue culture plates and treated with 2ng rTGFβ and 50U rMMP3. 
C) MiaPaCa cells were cultured on standard tissue culture plates and treated with AdGFP, AdTGFβ, AdMMP3, and 
AdRac1b (MOI=10). 
D) MiaPaCa cells were cultured on Matrigel-coated tissue culture plates and treated with AdGFP, AdTGFβ, AdMMP3, 
and AdRac1b (MOI=10). 
Small inserted graphs are detailed views of the lower bars, which do not appear well in the normal graph. 
Untreated and AdGFP treated cells respectively were used as controls. The expression of E-cadherin and Vimentin 
was normalized to the expression of RPLP0. * Symbolizes significance (p≤0.05) 
 
Summarized it appears, other than expected, that the elevated expression of Rac1b mediated 
by recombinant MMP3 did not result in increased EMT in S2-007 cells, the Vimentin expression 
stays nearly the same as in untreated cells. After adenoviral treatment, when Rac1b expression 
seemed to be dropped by AdTGFβ and AdMMP3 treatment (Figure 10), the Vimentin expression 
rose. However, MiaPaCa cells showed mesenchymal expression patterns in all cases of 
treatment, but once higher Vimentin expression after treatment with rMMP3 on Plastic, what 
goes along with a lower Rac1b expression. After adenoviral treatment, the same observations 
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were made for MiaPaCa as in S2-007 cells. These results, compared with the earlier ones (4.1.5.), 
confirm the assumption, that MMP3 might be a downstream target of MMP3 but that there 
must be some other mechanism and environmental impact (e.g. matrix compliance) to drive 
forward EMT (Nelson et al. 2008; Lee et al. 2012; Ungefroren et al. 2014). 
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4.2. In vivo experiments in triple transgenic mice 
Two triple transgenic mouse models were generated by mating tet-HA-MMP3, tet-YFP-Rac1b, 
tet-KRas, and rtTA-Ela1 mice, which were a kind gift from Derek C. Radisky. Because a defect in 
both alleles is lethal, the mice were mated first with FvB wild type mice to accrue an appropriate 
number of mice for mating to generate double transgenic rtTA-Ela1/tet-HA-MMP3, rtTA-
Ela1/tet-YFP-Rac1b, and rtTA-Ela1/tet-KRas mice. These mice were used for similar experiments 
as described in this work (data not show; dissertations N Voss and A Martin) and for mating to 
generate rtTA-Ela1/tet-HA-MMP3/tet-KRas and rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice. With 
these triple transgenic mice, the progression of pancreatic carcinoma following chronic 
pancreatitis with development of PanINs should be investigated. 
It was expected that the expression of KRas in addition to MMP3 and Rac1b would drive the 
development from chronic inflammation caused by Caerulein treatment to pancreatic cancer. 
Therefore, the mice were treated daily with 5µg/ml Caerulein or NaCl by intraperitoneal 
injection. They were fed without Doxycycline to express either MMP3 or Rac1b under the 
control of the elastase-1 promoter. This expression occurs specifically in exocrine pancreatic 
acinar cells that are presumed to be the cells of origin of PDAC. After 5 months, the mice were 
sacrificed and the pancreata were examined for PanINs and fibrosis. The expression levels of 
HA-MMP3 and YFP-Rac1b were determined by RT-qPCR. Additionally, the EMT-markers E-
cadherin, Smooth muscle actin (SMA), Amylase, and Cytokeratin 19 were investigated by 
immunohistochemistry and RT-qPCR.  
Previous experiments with double transgenic mice did not show a development of PanINs as 
expected. It just became apparent that the proliferation and the ADM under Caerulein 
treatment was increased (unpublished data). Therefore, it would be interesting to determine 
whether or not the presence of KRas would lead to PanIN and tumor development.  
 
4.2.1. The lack of Doxycycline activates tetracycline-controlled transgene 
Using a reverse tetracycline-controlled trans activator (rtTA) the transgene (MMP3, Rac1b) 
should be activated when Doxycycline, which is a tetracycline derivate, is absent. To assure that 
the transgene activation was put into effect, it was investigated, if the relative expression of HA-
MMP3 and YFP (Rac1b) was increased in transgenic mice fed without Doxycycline (-Doxy) 
compared to wildtype mice. Exemplary for this investigation the Rac1b results are shown in 
Figure 14 and Figure 15 (results for MMP3 were not representative). The activation of YFP in 
rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice in the absence of Doxycycline could be confirmed. In 
both experimental groups -Doxy/+Caerulein and -Doxy/-Caerulein YFP-Rac1b was detectable by 
immunohistochemistry. In mice treated with Caerulein the expression level of YFP-Rac1b 
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appeared to be lower (Figure 14 middle) than in mice treated without Caerulein (Figure 14 right) 
and Rac1b was localized around or in the nucleus, whereas it was cytoplasmic in Caerulein-
untreated tissue. The expression of YFP-Rac1b was increased 661fold in Caerulein-treated 
(Figure 15A) and nearly 50 000fold in Caerulein-untreated mice fed without Doxycycline (Figure 
15B). 
 
 
Figure 14; Histological staining for YFP tag of Rac1b in mice fed without Doxycycline 
Representative images of pancreatic tissue from rtTA-ela1/tet-YFP/tet-KRas mice. The YFP tag of Rac1b is very similar 
to the protein GFP. Therefore, it was stained with a rabbit antibody against GFP according to the described protocol 
(see 3.14.2). Doxycycline treated rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice served as control. Scale represents 100µm. 
 
 
Figure 15; Expression of YFP-Rac1b in rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice after 5 months of treatment 
A) The expression of YFP-Rac1b was investigated in rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice treated with 
Caerulein for 5 months. One experimental group was fed without Doxycycline to activate the transgene. 
Wild type mice treated with Caerulein were used as control group. 
B) The expression of YFP-Rac1b was investigated in untreated rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice (-Doxy/-
Caerulein). Wild type mice treated without Caerulein were used as control group. 
The expression of YFP-Rac1b was normalized to RPLP0. * symbolizes significance (p≤0.05) 
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4.2.2. Caerulein treatment after transgene activation results in distinct pancreatitis 
First, a HE staining was performed to investigate whether the tissue displayed chronic 
pancreatitis, ADM or evidence for PanINs or tumor development.  
Mice without Caerulein treatment had normal pancreatic tissue (Figure 16 left). When the 
transgene was inactivated, but the mice were treated with Caerulein, they developed mild 
chronic pancreatitis (Figure 16 middle), whereas Caerulein-treated mice with activated MMP3 
or Rac1b showed a more distinct pancreatitis (Figure 16 right). In this process the chronic 
pancreatitis developed stronger in rtTA-Ela1/tet-YFP-Rac1b/tet-KRas than in rtTA-Ela1/tet-HA-
MMP3/tet-KRas mice. Both mouse models showed ADM after Caerulein treatment, but they did 
not develop PanINs or PDAC. 
 
Figure 16; Development of chronic pancreatitis after 5 months of Caerulein treatment in triple transgenic mice 
Representative images of the development of chronic pancreatitis after Caerulein treatment in rtTA-Ela1/tet-HA-
MMP3/tet-KRas and rtTA-Ela1/tet-YFP-rac1b/tet-KRas mice depends on the absence or presence of Doxycycline and 
the accompanied transgene activation or inactivation. When either MMP3 or Rac1b are activated, the pancreatitis 
was more distinct and appeared with ADM. 
 
 
4.2.3. Variable ADM occurrence after activation of MMP3 and Rac1b overexpression 
Acinar to ductal metaplasia (ADM) is an indicator for EMT-independent transformation of 
epithelial tissue. To quantify the amount of ADM occurrences the ratio between Amylase and 
CK19 was calculated. A higher quotient indicates a high Amylase expression, which is an 
indicator for existence of acini. A lower quotient signifies a high CK19 expression and represents 
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the formation to ductal cells and therefor the presence of ADM. Mice with activated transgene 
but without chronic pancreatitis (-Doxy/-Caerulein) were used as reference for mice with 
chronic inflammation (+Caerulein). 
From the statistics of expression levels, it was found that rtTA-Ela1/tet-HA-MMP3/tet-KRas mice 
with chronic pancreatitis but inactivated transgene showed the greatest extent of ADM (Figure 
19). For HA-MMP3 mice fed without Doxycycline the ratio was higher (ratio = 0.0127) than in 
the same transgenic mice fed with Doxycycline (ratio = 0.0012). This could be confirmed 
histologically. HA-MMP3 mice with activated transgene seem did not show such a strong CK19 
staining like the mice with inactivated transgene. Additionally, both showed a strong Amylase 
staining, too (Figure 17 middle and right). This is reflected in a higher ratio of expression of 
Amylase and CK19 in mica with activated transgene (Figure 19A). 
For rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice the data implicate a higher ADM occurrence in mice 
with activated transgene (ratio = 0.0094) (Figure 19B). This coincides with the histological 
staining where the CK19 staining was strongest and the Amylase staining was weaker than in 
YFP-Rac1b mice with inactive Rac1b (Figure 18 middle and right). Taken together these results 
implicate a higher ADM occurrence after inducing chronic pancreatitis for both transgenes and 
additionally for overexpression of YFP-Rac1b. 
 
 
Figure 17; Amylase and CK19 in rtTA-Ela1/tet-HA-MMP3/tet-KRas mice after 5 months of treatment 
Representative images of Amylase and CK19 staining in tissue from HA-MMP3 mice. Scale bar represents 100µm. 
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Figure 18; Amylase and CK19 in rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice after 5 months of treatment 
Representative images of Amylase and CK19 staining in tissue from YFP-Rac1b mice. Scale bar represents 100µm. 
 
 
Figure 19; Ratio of Amylase to CK19 in rtTA-Ela1/tet-HA-MMP3/tet-KRas and rtTA-Ela1/tet-YFP-Rac1b/tet-KRas 
mice after 5 months of treatment 
A) rtTA-Ela1/tet-HA-MMP3/tet-KRas and rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice were treated without 
Caerulein and fed without Doxycycline. Wild type mice treated without Caerulein were used as control 
group. 
B) rtTA-Ela1/tet-HA-MMP3/tet-KRas and rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice were treated with Caerulein 
and fed with Doxycycline. Wild type mice treated without Caerulein were used as control group. 
The expression of Amylase and CK19 was normalized to RPLP0 and the ratio from both expression levels was 
generated. * symbolizes significance (p≤0.05) 
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4.2.4. Proliferation potential depends on inflammation and transgene activation 
Ki67 is nuclear protein that is well known as a proliferation marker. Due to its association with 
active cell cycle phases (G1, S, G2, M phase) (Gerdes et al. 1983) its nuclear localization varies 
during the cell cycle in a phosphorylation status-dependent manner (MacCallum & Hall 1999). 
The Ki67 staining was performed by Dr. Ramaswamy (Institute of Pathology; 
Universitätsklinikum Marburg). Positively stained cells or nuclei, respectively, were scored in 
proportion to all hematoxylin-stained nuclei. 
 
 
Figure 20; Ki67 staining in rtTA-Ela1/tet-HA-MMP3/tet-KRas mice after 5 months of treatment 
Representative staining of Ki67 in pancreatic tissue from rtTA-Ela1/tet-HA-MMP3/tet-KRas mice after 5 months of 
treatment with or without Caerulein and Doxycycline. Scale bar represents 100µm. 
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Figure 21; Ki67 staining in rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice after 5 months of treatment 
Representative staining of Ki67 in pancreatic tissue from rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice after 5 months of 
treatment with or without Caerulein and Doxycycline. Scale bar represents 100µm. 
 
In pancreatic tissue from rtTa-Ela1/tet-HA-MMP3/tet-KRas (Figure 22A) and rtTa-Ela1/tet-YFP-
Rac1b/tet-KRas (Figure 22B) mice treated without Doxycycline and without Caerulein, more Ki67 
positive cells (2.16% and 2.12%) were found than in tissue from untreated wild type mice 
(0.61%). The Ki67 staining in mice with activated transgene, but without chronic inflammation 
was found mainly at the nucleus, but also punctually located in the cytoplasm. This pattern was 
found also in wild type mice (Figure 20 and Figure 21 upper panel). In wild type mice treated 
with Caerulein, the ratio of Ki67 positive cells was elevated up to 25.39% and Ki67 was located 
at the nucleus (Figure 20 and Figure 21 lower panel, left). Transgenic mice treated without 
Doxycycline and with Caerulein (activated transgene, chronic pancreatitis) showed with 28.65% 
(HA-MMP3; Figure 22A) and 22.26% (YFP-Rac1b; Figure 22B) the highest percentage of Ki67 
positive cells, and Ki67 was localized at the nucleus (Figure 20 and Figure 21). The same 
localization was found in tissue from mice treated with Doxycycline and Caerulein (inactivated 
transgene, chronic pancreatitis). In rtTa-Ela1/tet-HA-MMP3/tet-KRas mice (Figure 22A) the 
number of positive cells was calculated to be 16.56% and in rtTa-Ela1/tet-YFP-Rac1b/tet-KRas 
mice (Figure 22B) the percentage of Ki67 positive cells was 12.68%. In summary, these results 
show that the number of Ki67 positive cells mainly depends on the existence of chronic 
pancreatitis and is only partially influenced by MMP3 or Rac1b overexpression. The number of 
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proliferating and therefore Ki67 expressing cells seem to be more affected by MMP3 
overexpression than by Rac1b overexpression. The localization of Ki67 only depends on the 
inflammatory status of surrounding tissue and not on the activation of MMP3 or Rac1b 
overexpression. 
 
 
Figure 22; Percentage of Ki67 positive cells in triple transgenic mice 
Pancreatic tissue from rtTA-Ela1/tet-HA-MMP3/tet-KRas and rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice was stained for 
Ki67. The positive cells were counted per field of view and their percentage of all pancreatic cells was calculated. 
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4.2.5. MMP3 activation did not show an influence on EMT markers whereas Rac1b does 
For the investigation of typical EMT markers histological staining and RT-qPCR were performed. 
Staining of E-cadherin as a typical epithelial marker and of SMA as typical mesenchymal marker 
were performed as described under 3.14.2.  
The pancreata of wild type mice treated without Caerulein (WT; -Caerulein) showed the regular 
structure of healthy pancreatic tissue and E-cadherin could be found along all cell-cell contacts. 
Compared to the staining of blood vessels, SMA was weaklier stained in pancreatic cells (Figure 
23 and Figure 24). A different staining pattern was found in wild type mice treated with Caerulein 
(WT; +Caerulein). The homogenous structure of the pancreas was lost and replaced by ducts 
and connective tissue. Here, E-cadherin was found in only a few cells and at the inner cell-cell-
contacts of the ducts. SMA staining was much weaker in pancreatic tissue than in blood vessels 
(Figure 23 and Figure 24). In untreated rtTA-Ela1/tet-HA-MMP3/tet-KRas mice fed without 
Doxycycline (-/-) the staining pattern of E-cadherin and SMA mimics the staining pattern in wild 
type mice without Caerulein treatment (Figure 23). This implies that the activation of MMP3 had 
no influence on the expression of typical EMT markers when there is no inflammatory 
background. The same seems to be true when chronic pancreatitis is present. The staining 
pattern of E-cadherin and SMA in tissue from HA-MMP3 mice with or without activated MMP3 
and treated with Caerulein (-/+ and +/+) did not differ from Caerulein-treated wild type mice 
(Figure 23). Only the degree of chronic pancreatitis was influenced as described before. 
Therefore, the SMA staining was a bit higher in HA-MMP3 mice with inactivated MMP3 that also 
show a more distinct pancreatitis (Figure 23). The E-cadherin staining in rtTA-Ela1/tet-YFP-
Rac1b/tet-KRas mice fed without Doxycycline and without Caerulein (-/-), was found along all 
cell-cell contacts as it was seen in untreated wild type mice. The SMA staining was comparable 
to that of blood vessels found in this section (Figure 24). YFP-Rac1b mice fed without Doxycycline 
and treated with Caerulein (-/+) presented a stronger chronic pancreatitis than YFP-Rac1b mice 
with inactivated Rac1b (+/+). In addition, E-cadherin was found in -/+ Rac1b mice at the inner 
cell-cell-contacts of the ducts, whereas +/+ Rac1b mice showed an E-cadherin staining pattern 
similar to wild type mice. The ducts of these mice presented a SMA staining at the outer borders 
(Figure 24). This is evidence for the occurrence of EMT in the pancreatic tissue of YFP-Rac1b 
mice with activated transgene on the background of chronic inflammation and ADM. The SMA 
staining in +/+ Rac1b mice was as weak as in wild type mice treated with Caerulein. In summary, 
the results show that MMP3 seems not to influence the EMT machinery, whereas Rac1b 
activation on the background of inflammation influences the expression of typical EMT markers 
in cells undergoing ADM. 
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Figure 23; E-cadherin and SMA staining in rtTA-Ela/tet-HA-MMP3/tet-KRas mice after 5 months of treatment 
Representative images of pancreatic tissue from rtTA-Ela1/tet-HA-MMP3/tet-KRas mice after 5 months of treatment 
with or without Caerulein and Doxycycline. Tissue sections were stained with HE and for E-cadherin and SMA 
according to described protocols. Scale bar represents 100µm. 
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Figure 24; E-cadherin and SMA staining in rtTA-Ela/tet-YFP-Rac1b/tet-KRas mice after 5 months of treatment 
Representative images of pancreatic tissue from rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice after 5 months of treatment 
with or without Caerulein and Doxycycline. The same wild type stainings as show in Figure 25 can be used as control. 
Tissue sections were stained with HE and for E-cadherin and SMA according to described protocols. Scale bar 
represents 100µm. 
 
 
4.2.6. Transgene activation influences EMT marker expression other than expected 
Although we had problems by providing the evidence for activation of HA-MMP3, we could 
prove the activation of YFP-Rac1b expression and the induction of chronic pancreatitis by 
Caerulein. Therefore, the expression levels of E-cadherin and Vimentin were investigated by RT-
qPCR to determine if their levels were influenced by the potential activation of HA-MMP3 and 
YFP-Rac1b. 
The expression levels of E-cadherin and Vimentin in rtTA-Ela1/tet-HA-MMP3/tet-KRas mice fed 
without Doxycycline, but without chronic pancreatitis (- Caerulein), showed a typical epithelial 
pattern. The level of E-cadherin was doubled compared to wild type mice, whereas that of 
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Vimentin was decreased (Figure 25A). When the mice were treated with Caerulein and 
developed chronic pancreatitis (Figure 25B), the expression levels of E-cadherin were elevated 
by 5.5-fold and 2-fold compared to wild type mice treated with Caerulein. Again, the expression 
of Vimentin was very low (0.02 and 0.01) and it seemed to be independent of the transgene. 
These results go along with the potentially missing transgene activation. 
 
 
Figure 25; Expression of E-cadherin and Vimentin in rtTA-Ela1/tet-HA-MMP3/tet-KRas mice after 5 months of 
treatment 
A) rtTA-Ela1/tet-HA-MMP3/tet-KRas mice were treated with Caerulein and fed without Doxycycline. Wild type 
mice treated without Caerulein were used as control group. 
B) rtTA-Ela1/tet-HA-MMP3/tet-KRas mice were not treated with Caerulein and fed without Doxycycline. Wild 
type mice treated without Caerulein were used as control group. 
The expression of E-cadherin and Vimentin was normalized to RPLP0. 
 
The expression of E-cadherin and Vimentin in rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice is shown 
in Figure 26. In summary, the results were the same as in rtTA-Ela1/tet-HA-MMP3/tet-KRas 
mice. The E-cadherin expression was elevated independent of chronic pancreatitis and YFP-
Rac1b activation. Just the level of elevation differs from 4fold (-Doxy/+Caerulein) over 5.5fold (-
Doxy/-Caerulein) to 7.3fold (+Doxy/+Caerulein). The Vimentin expression is low in all three 
cases, which indicates that no EMT had taken place after YFP-Rac1b activation. In summary, the 
results show that EMT is independent of the activation of HA-MMP3 or YFP-Rac1b and the 
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presence or absence of chronic pancreatitis and PanINs. Other than expected, EMT seems to 
take place only in cancer and not in transforming tissue. 
 
 
Figure 26; Expression of E-cadherin and Vimentin in rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice after 5 months of 
treatment 
A) rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice were treated with Caerulein and fed without Doxycycline. Wild type 
mice treated without Caerulein were used as control group. 
B) rtTA-Ela1/tet-YFP-Rac1b/tet-KRas mice were not treated with Caerulein and fed without Doxycycline. Wild 
type mice treated without Caerulein were used as control group. 
The expression of E-cadherin and Vimentin was investigated by RT-qPCR and normalized to RPLP0. 
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5. Discussion 
The activation of the EMT program has been proposed to be a critical mechanism during the 
multiple stages of tumor progression for the acquisition of malignant phenotypes that are 
associated with cell migration and invasiveness (Thiery 2002; Huber et al. 2005). It has been 
shown that cells undergoing EMT are mainly seen at the invasive tumor front and these are the 
cells entering the invasion-metastasis cascade, i.e. intravasation and transport through the 
circulation (Thiery 2002; Thiery et al. 2009). The reverse process, MET, is necessary for cells to 
form secondary tumors after extravasation (Zeisberg et al. 2005). Although the full spectrum of 
signaling agents contributing to EMT remain unclear, it is known that signals transmitted from 
tumor stroma, such as TGFβ, appear to be responsible for the induction of EMT-inducing 
transcription factors (Thiery 2002; Song 2007). TGFβ seems to be the most important soluble 
EMT-inducer, but it depends on a complex network of other pathways, such as the 
SMAD4/STAT3 (Zhao et al. 2008) and the MAPK/ERK (Ellenrieder et al. 2001; Maier, Wirth, et al. 
2010) signaling pathways. Additionally, there is evidence that TGFβ-induced EMT requires the 
activation of NFκB (Maier, Schmidt-Strassburger, et al. 2010). In contrast to other studies, which 
showed Rac1b to promote EMT (Radisky et al. 2005; Stallings-Mann et al. 2012; Waldmann et 
al. n.d.) Ungefroren et. al. showed that Rac1b antagonizes TGFβ1 induced cell migration by 
suppressing the phosphorylation, and therefore, the function of SMAD3. A suppression of 
SMAD3 not only results in a reduced migration potential, but also may cause a disruption of 
SMAD4-mediated EMT signaling (Ungefroren et al. 2014).  
Based on gene array data, it was found that MMP3 was not detectable in pancreatic cancer cells 
(Tjomsland et al. 2016), a fact that could be confirmed with the pancreatic cancer cell lines that 
were used for this thesis. However, it was shown that the treatment of mouse cells in culture 
and pancreatic cell lines (8988T, Panc1) with MMP3 is directly responsible for the induction of 
EMT (Lochter et al. 1997; Mehner et al. 2014) and that in mammary epithelial cells treated with 
MMP3 this induction is associated with the loss of E-cadherin (Radisky et al. 2005). Additionally, 
it was shown that MMP3 induces EMT through a cascade that involves the activation of Rac1b 
and the production of ROS (Radisky et al. 2005). We found that the treatment with recombinant 
MMP3 elevated the expression of Rac1b in the pancreatic cancer cell line S2-007, whereas 
MiaPaCa cells showed a slightly reduction of Rac1b expression after treatment with recombinant 
MMP3. Also, the inhomogeneous results for EMT marker expression in S2-007 and MiaPaCa cells 
showed that the investigation of EMT is heavily depending on the experimental context.  
It was described that tissue stiffness has positive effects on EMT induction and that 
microenvironment with physiological normal compliance, as found with Matrigel, acts in a 
protective manner on EMT-induction by MMP3, whereas the TGFβ-mediated EMT is not 
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affected by substratum rigidity (Lee et al. 2012). We could not confirm that AdRac1b induces 
EMT on stiff (plastic), but not on soft (Matrigel) substrates as described by Lee et al. in 2012. 
Rather the AdRac1b treatment of S2-007 cells cultured on Matrigel resulted in a highly-elevated 
expression of Vimentin compared to AdGFP-treated cells. Although the results did show a high 
fluctuation, AdRac1b treatment resulted in 10fold (Plastic) and 10 000fold higher expression 
compared to the treatment with AdTGFβ or AdMMP3. Other studies showed that, to produce 
ROS, a localization of Rac1b at the membrane is essential. At the cell membrane, it can interact 
with components of the membrane-associated enzyme NADPH oxidase to promote ROS 
production and EMT. The intracellular localization of Rac1b depends on α5-integrin and on α6-
integrin that is expressed in cells growing on laminin rich ECM, such as Matrigel (Chen et al. 
2013). On soft, laminin rich substrates α6-integrin can keep Rac1b localized in the cytoplasm and 
there it delocalizes to the cell periphery and the membrane ruffles. This means, that Rac1b is 
not able to interact with components of the NADPH enzyme complex to produce Ros and to 
induce EMT (Lee et al. 2012). It is possible that the overexpression of Rac1b, mediated by 
adenoviral treatment, might overcome the effect of α6-integrin in cells cultured on Matrigel 
because of a remarkably high number of molecules and therefore, Rac1b can bind at the 
membrane and induce the EMT machinery, which results in a high Vimentin and a lower E-
cadherin expression. Both integrins, α5 and α6, are also responsible for the EMT induction by 
MMP3. The mechanisms are not completely understood, but it was shown that α6-integrin 
transmits signals from laminin rich ECM to block EMT, but is not sufficient to inhibit EMT in 
general. On the other side α5-integrin is necessary for the MMP3-induced EMT in standard 
conditions (Chen et al. 2013). 
The lower induction of EMT after AdMMP3 treatment can be explained by the fact that EMT 
induction depends on cell spreading which is a consequence of MMP3-mediated Rac1b 
induction (Nelson et al. 2008). Induction of EMT by MMP3/Rac1b depends on the density in 
which cells were cultured. It might be possible that especially S2-007 cells have overgrown, 
which means that the ability to change cell shape was limited, but it is required for the MMP3-
induced EMT and seem to be important for EMT promotion by ROS production (Nelson et al. 
2008). Again, the investigations seem to be prone to highly constant experimental settings, such 
as cell density, matrix, and the kind of overexpressed protein. This might influence the 
occurrence of EMT during different experiments and result in inhomogeneous findings. It is 
suspected that cancer cells do not undergo EMT completely, but only partially, thereby acquiring 
new mesenchymal characteristics while maintaining some epithelial characteristics (Hanahan & 
Weinberg 2011). In the case of MiaPaCa cells, which was defined as a poorly differentiated cell 
line having lost the ability to form cell-cell contacts (Sipos et al. 2003), a naturally mesenchymal 
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behavior influences the results in a EMT-positive manner.  This means that the S2-007 cells might 
exhibit epithelial-specific morphology and expression of epithelial markers, such as CK19 and E-
cadherin, but also show expression of mesenchymal markers, such as Vimentin or α-SMA. These 
cells represent the intermediate stages of EMT (Kalluri & Weinberg 2009), whereas MiaPaCa 
cells represent a mesenchymal cell line with unmutated SMAD4 (Sipos et al. 2003) and therefore 
functional TGFβ signaling. 
It is not clear in which way the different localization patterns of Vimentin influences the 
occurrence of EMT, but it was reported that the localization of Vimentin at the nuclear envelope 
is accompanied by an interaction with Lamin B to set contacts between the karyoskeleton and 
the plasma membrane skeleton (Georgatos & Blobel 1987). Additionally, it was shown that 
nuclear localized Vimentin can induce DNA-mediated events and that it can act as a regulator of 
transcription (Traub & Shoeman 1994; Mergui et al. 2010). Other studies described an 
interaction of Vimentin with cytoplasmic proteins, such as ERK, AKT1, and Scrib and that 
Vimentin localized at the plasma membrane can be regulated by TGFβ (Perlson et al. 2006; Phua 
et al. 2009; Yin et al. 2006). The influence of MMP3 and Rac1b overexpression to localization of 
Vimentin in S2-007 and MiaPaCa cells, the relationship to EMT occurrence, as well as the 
influence of MMP3 and Rac1b on other EMT-associated molecules should be investigated in 
more detail in further in vitro experiments. Then it would be advising to adjust the experimental 
settings of this very complex system for its dependency to kind and pulse of stimulation even 
more. 
 
In a study similar to the present one, it was shown that the co-expression of MMP3 and KRas in 
transgenic mice lead to alterations in acinar cells and the recruitment of immune cells, which 
primes a stromal microenvironment (Mehner et al. 2014). In the context of these findings I used 
a related mouse model and induced chronic pancreatitis to investigate whether the co-
expression of MMP3 and mutated KRas is also sufficient to cause pancreatic cancer on the 
background of already existing inflammation. We found that after 5 months of treatment the 
alterations of acinar cells arose to ADM, but neither PanINs nor PDAC were detectable. In some 
other studies, mouse models expressing activated mutants of KRas at endogenous levels, 
develop precursor lesions, such as higher grade PanINs, which either did not progress to PDAC 
or even within 1-2 years (Hingorani et al. 2003; Ji et al. 2009). If LSL-KRas/Ela-CreERT mice were 
crossed with a conditional p53 deletion mice, most of the offspring develop PDAC within 6 
month (Ji et al. 2009). Similar observations were made by Guerra et al. where mice develop 
moderately to poorly differentiated PDACs only, when they carry both KRasG12V and mutant p53. 
They summarize from several experiments that mutated KRas alone has just a few consequences 
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for adult acinar cells (Guerra et al. 2007). Mutated KRas needs various stimuli, such as TGFα to 
mediate inflammation (Siveke et al. 2007) without external stimuli, such as Caerulein, which we 
were using to promote chronic pancreatitis. Also, further genetic alterations beyond KRas 
mutation are required for development of pancreatic lesions and PDAC (Guerra et al. 2007; 
Logsdon & Ji 2009).  Not having used additional p53 or other deletions, might explain why the 
CP of my transgenic mice did not develop into PanINs or PDAC. Additionally, we made our 
investigations after a comparatively short period of 5 months, which could explain the lack of 
PanINs and PDAC development in MMP3 mouse models. Also, for my Rac1b expressing mouse 
model, it might be better to investigate over an extended time period, as it was described by 
Stallings-Mann et al. in 2012 that the development of lung cancer in transgenic mice under 
Rac1b overexpression occurs after 60 weeks. 
The next step in studying the influence of MMP3 and Rac1b during development and 
progression of pancreatic cancer was the investigation of EMT markers after transgene 
activation. The results from immunohistochemistry and RT-qPCR suggest that MMP3 did not 
have an influence on the EMT machinery in vivo. Complicating, the activation of HA-MMP3 was 
not clearly detectable. That means, a missing EMT effect could be caused by a missing transgene 
activation and has no molecular reasons.  But why did the activation of Rac1b expression show 
evidence for EMT in immunohistochemistry, but not in RT-qPCR? Since EMT is a transient event 
and is reversible, we suggest that EMT mainly occurs in transforming tissue, such as PanINs or 
in tumor cells, neither of which did I detected.  
In summary, my results suggest that the direct influence of MMP3 is not as high as expected and 
seems to depend on some other factors, which were not investigated here. For further in vitro 
studies, it might be necessary to focus on the TGFβ and NFκB signaling pathways and their 
relationship to MMP3 and Rac1b. Especially for Rac1b, it is controversial whether or not it is an 
activator for NFκB (Matos et al. 2003; Matos & Jordan 2005; Singh et al. 2004). Also, Rac1b was 
shown to interact with TGFβ itself or components of the TGFβ-induced EMT pathway, such as 
SMAD3 in different ways (Ungefroren et al. 2014). A mouse model containing tetracycline 
controlled TGFβ might be helpful for similar investigations performed in vivo. Additionally, it will 
be required to investigate the reciprocal effect of KRas on MMP3/Rac1b-mediated EMT on the 
background of chronic pancreatitis for a longer period. 
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